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ABSTRACT 
This study identified risk factors for pain intensity at rest and with movement, pain 
qualities and neuropathic pain 24 hours post-breast cancer surgery (BCS). Before surgery 86 
women completed demographic, health status, and psychological questionnaires and blood was 
drawn to measure baseline cytokine levels. Numeric Rating Scale-Rest (NRS-R), NRS-Movement 
(NRS-M), Short-Form McGill Pain Questionnaire (SF-MPQ) and Short-Form Neuropathic Pain 
Questionnaire (SF-NPQ) were completed 24 hours post-BCS. Backward regression models found 
significant correlates for NRS-R: younger age, increased pain catastrophizing and bilateral 
surgery; NRS-M: younger age, increased trait anxiety, bilateral surgery, and mastectomy; SF-
MPQ: increased pain catastrophizing, bilateral surgery, and previous breast surgery; and SF-NPQ: 
decreased interleukin-10 and increased pain catastrophizing. These results support the 
biopsychosocial model of pain and the importance of measuring multiple pain outcomes. 
Variables accounting for the most variance in each outcome (pain catastrophizing [NRS-R; SF-
MPQ], trait anxiety [NRS-M] and baseline IL-10 [SF-NPQ]) are potentially modifiable. 
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1 INTRODUCTION  
Breast cancer is the most common cancer affecting Canadian women with 26,300 
expected diagnoses in 20171. Mortality from breast cancer has declined since the mid-1980s, and 
the current five-year survival rate is 87%1. This increased survivorship warrants a focus on 
preventing and reducing treatment sequelae. Surgery remains frontline treatment, however, it 
is associated with acute post-surgical pain (APSP) in 15-60% of patients2,3. APSP can lead to 
complications involving multiple organ systems, psychological distress, reduced patient 
satisfaction, delayed discharge from hospital, unanticipated readmissions and persistent post-
surgical pain (PPSP)4.  
Pain is a biopsychosocial construct and therefore, to elucidate risk factors for APSP 
considering multiple dimensions is essential. In the biological domain, various inflammatory 
cytokines have been implicated suggesting they could be effective biomarkers to identify those 
at risk for APSP. However, most research has examined chronic pain populations or the post-
operative inflammatory response rather than baseline levels. Studies on APSP have mostly 
focused on demographic, surgical and psychological risk factors. The current study was the first 
to our knowledge to develop models of APSP intensity at rest, with movement, general pain 
qualities and neuropathic pain (NeP) qualities after breast cancer surgery (BCS) using pre-
operative factors, including baseline cytokine concentrations, demographic, biological and health 
status, surgical, and psychological variables. Identifying patients at high-risk for APSP and 
modifiable risk factors will allow tailored analgesic, psychosocial and educational initiatives, 
which may reduce the burden of APSP. 
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2 CURRENT STATE OF KNOWLEDGE AND RATIONALE 
2.1 Breast Cancer Surgery  
Most patients with breast cancer undergo lumpectomy or mastectomy, and possibly 
sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND)5,6. Lumpectomy 
removes the tumour and some healthy tissue5,6. Mastectomy removes the entire breast and can 
be followed by immediate or delayed reconstruction5,6. SLNB removes the first lymph nodes from 
around the tumour and is performed to determine if there is involvement5,6. If there is, then 
ALND, the removal of 10-40 lymph nodes from the axilla, will be carried out to determine the 
extent of the spread5,6.  
Unfortunately, post-BCS pain has been reported to occur in 15-60%2,3 of patients, and on 
average women report moderate pain in the post-anesthesia recovery room3. However, APSP 
varies widely with some patients reporting minimal pain and others experiencing severe pain7.  
 
2.2 Pain Definition, Mechanisms and Theories 
Pain is a multidimensional experience defined by The International Association for the 
Study of Pain as “an unpleasant sensory and emotional experience associated with actual or 
potential tissue damage, or described in terms of such damage”8. Nociceptive pain is triggered 
by tissue damage and is usually throbbing, aching or pressure-like. NeP results from a lesion or 
disease of the somatosensory nervous system and is typically lancinating, shooting, electric-like 
or stabbing9. Often acute NeP occurs simultaneously with nociceptive pain10. Most attention to 
post-surgical NeP focuses on chronic NeP which occurs in 20-69% of patients11. Few studies 
distinguish between nociceptive and NeP in the acute period despite different etiologies and 
management strategies. Other terms commonly used to describe pain that do not imply an 
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underlying mechanism include: allodynia – pain from a stimulus that does not normally cause 
pain12, and hyperalgesia – increased pain from a stimulus that normally causes pain12.  
Gate Control Theory  
Melzack and Wall’s (1965) Gate Control Theory (GCT), proposes that skin stimulation 
induces nerve impulses that are transduced by peripheral nociceptors to the dorsal horn13. At the 
dorsal horn, the impulse is integrated with signals from other afferent neurons, interneurons and 
descending modulatory signals14. This modulation affects the membrane potential of afferent 
fiber terminals and determines the excitatory effect of incoming impulses13. The balance 
between nociceptive and facilitatory signals with non-nociceptive and inhibitory signals in the 
dorsal horn will determine if the gate will be “open” or “closed”, dictating whether the signal will 
be propagated to the brain13,15. Negative emotions, such as helplessness and anger, “open” the 
gate, while positive behaviours such as stress reduction “close” the gate16. Importantly, this 
theory proposes one possible mechanism for the influence of higher cortical functions on the 
subjective perception of pain. 
The GCT continues to be the most widely accepted model of pain17,18. In 1999, Melzack 
updated the GCT, proposing the neuromatrix theory of pain, which defines pain as a 
multidimensional experience generated by a complex neural network in the brain rather than 
directly by sensory input19. In the following sections, I will first discuss the transmission of a 
nociceptive signals from the periphery to the central nervous system. Then I will explore the 
neuromatrix theory of pain and the complex interactions that occur within the central nervous 
system. Following that, I will explore how injury, such as surgery, may influence neurobiological 
changes in both the peripheral and central nervous systems and how cytokines influence these 
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processes. I will finish by exploring the evidence for various risk factors in the development of 
post-operative pain.  
Nociception 
The process of nociception begins when a noxious stimulus or tissue damage, such as 
that occurring during surgery, activates peripheral nociceptors20. Nociceptors are sensory 
afferent fibres that respond to external and internal stimuli but are normally silent, only 
transmitting signals when a given threshold is reached21. Afferent fibres, whose cell bodies lie 
predominantly in the dorsal root ganglion (DRG), enter into grey matter of the spinal cord as 
dorsal roots and terminate primarily in the dorsal horn where the incoming signals are modified 
by many interacting neurons14. The signal is then transmitted to projection neurons that ascend 
to the brain22. Ad and C afferent fibres, which carry predominantly nociceptive signals, terminate 
mainly in the tip of the dorsal horn, which corresponds to the substantia gelatinosa or Rexed’s 
laminae I-II23. These fibres principally release the excitatory neurotransmitter glutamate14. Low-
threshold subsets of Ad and C afferent fibres, that respond to non-noxious stimuli also exist24. 
Low-threshold Ab fibres and low threshold Ad and C fibres, responsible for transmitting tactile 
information, terminate primarily in laminae II-IV25.  
Some projection neurons ascend to nuclei in the thalamus while others ascend to other 
brain regions including the parabrachial nucleus, the midbrain periaqueductal grey (PAG), the 
reticular formation, the hypothalamus, the nucleus of the solitary tract, and the ventrolateral 
medulla14,24. The projection neurons that reach these regions in the brain then synapse with 
other neurons that extend to higher cortical areas of the brain, including the somatosensory 
cortices, insula, anterior cingulate cortex (ACC) and prefrontal cortex22,26–28.  
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Dorsal Horn Integration 
Afferent fibres interact with interneurons and directly with ascending projection neurons 
in the dorsal horn14. Interneurons may be excitatory or inhibitory, and these neurons receive 
input from primary afferent fibres, other interneurons, as well as from descending pathways29–
31. Some inhibitory interneurons receive input from Ab fibres and synapse with afferents 
innervating excitatory interneurons, causing presynaptic inhibition32,33. Other inhibitory 
interneurons receive input from nociceptive afferents and synapse with either excitatory or 
inhibitory interneurons33,34. Different types of excitatory interneurons also receive inputs from 
Ad and C afferent fibres35, while others respond to Ab fibres33,34. Inhibitory interneurons mediate 
their effect primarily via gamma-aminobutyric acid (GABA) and glycine, while excitatory 
interneurons release glutamate29,33–35.  
Consistent with the conceptual GCT, the total input to projection neurons directly from 
primary afferent fibres and from a variety of interneurons, determines whether a signal will be 
transmitted along the ascending pathways24. Projection neurons found in lamina I contain most 
of the nociceptive-responsive ascending fibres34. Projection neurons in deeper laminae, 
particularly lamina V, have wide dynamic range neurons that respond to both nociceptive and 
innocuous stimuli24. The integration of signals in the dorsal horn is complex and various cell types 
and interactions continue to be elucidated however, current evidence continues to support the 
GCT.  
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Descending pathways 
As suggested by Melzack & Wall in the GCT, descending pathways from the brain to the 
dorsal horn allow psychological factors to contribute to processing of nociceptive stimuli36. These 
descending inputs influence which signals are transmitted, ensuring information relevant to a 
given situation is received, while other less relevant signals are silenced23. Descending pathways, 
which contain serotonergic neurons, noradrenergic neurons, and dopaminergic neurons, as well 
as neurons that release GABA and endogenous opioids demonstrate both inhibitory and 
facilitatory effects directly on dorsal horn neurons and via interneurons in the dorsal horn37. This 
contributes to the “gating” function in the spinal cord and affects whether a nociceptive signal 
from Ad and C fibres will be transmitted to nociceptive responsive ascending neurons38.  
Descending modulation may be influenced by context (pain beliefs, expectation, past 
experiences), cognition (attention, catastrophizing), mood (depression, anxiety), genetics and 
neurochemical changes39. The prefrontal cortex40, ACC41, amygdala42,43, hypothalamus44, PAG43,45 
and rostral ventromedial medulla (RVM)43,46 have all been implicated in the descending 
modulatory systems. Importantly, many of these pathways are involved in or receive inputs from 
areas of the brain associated with emotion, fear, anxiety, and other higher order functions37.  
Some descending pathways have been well characterized while others are still being 
clarified. One of the most clearly described involves fibres descending from the RVM in the 
midbrain to the dorsal horn46. The RVM receives input from the PAG, the nucleus cuneiformis, 
prefrontal cortex, the amygdala and the ACC28,47. The RVM can have both an inhibitory and 
facilitatory effect, mediated through different cell types which is beyond the scope of this 
thesis48,49 (see Heinricher et al. (2009)46 for more details). The effect in the dorsal horn depends 
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on the balance of inputs from the inhibitory and facilitatory cells28. The various higher cortical 
areas with connections to the RVM descending pathway is one of many top-down systems 
implicated in the complex modification of nociceptive signals (see Millan (2002)38 for an in-depth 
review).  
Neuromatrix Model of Pain 
Melzack later developed the neuromatrix model of pain which builds on the GCT19,36. The 
neuromatrix involves networks of neurons, with loops connecting the thalamus and cortex and 
cortex and limbic system19. This network is initially genetically determined and modified by 
sensory inputs19. These loops diverge allowing processing in different regions of the brain and 
converge leading to integration of different processing outputs19. Melzack proposed that inputs 
to the neuromatrix include: cognitive related brain areas (past experiences, attention, memory, 
anxiety), sensory signaling systems (cutaneous, visceral, musculoskeletal) and emotion related 
brain areas (limbic system and associated homeostatic and stress responses)19,50. These different 
dimensions of processing lead to outputs, referred to as the neurosignature, that travel to various 
brain areas to produce pain perception (sensory, affective, and cognitive dimensions), action 
responses (involuntary and voluntary movement) and stress regulation (cortisol, noradrenaline, 
endorphin and immune system responses)50.  
The pain neuromatrix is thought of as having two parts: a lateral component, which 
includes the somatosensory cortices, thalamus and posterior insula and is primarily responsible 
for sensory-discriminative aspects of pain; and a medial component, consisting of the anterior 
insula, ACC and prefrontal cortex, responsible for the affective-evaluative-cognitive aspect of 
pain26,27,39,51. However, this proposed ‘matrix’ is dynamic and different components may be 
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activated in different situations, which could contribute to some of the disparities reported in 
functional magnetic resonance imaging (fMRI) studies examining components of the pain 
matrix39.  
The primary regions involved in pain processing include somatosensory cortices52–59, 
insula52–54,56–61, ACC41,56–58,61, prefrontal cortex57,58,61,62 and thalamus52,53,56–58,60,61,63 (see Apkarian 
et al. (2005)64 meta-analysis). Other areas including the basal ganglia65, cerebellum58, amygdala 
and hippocampus43,56,66 may also be activated depending on the individual and context39. 
Activation of motor areas was also observed 56–58,61,63 supporting that the output from the 
neuromatrix contributes to motor responses, as proposed by Melzack19.  
Importantly, many of the regions involved in the pain neuromatrix are also involved in 
emotional processing and cognitive functions and activity in various areas involved in the 
neuromatrix are differentially activated in different emotional states67. The outcome of these 
interacting factors that vary for each individual in different situations is proposed to, in part, 
explain varied pain experiences16, such as seen after BCS68. Functional imaging studies have 
supported that varied activation and connectivity between different brain regions is related to 
different pain experiences69.  
 
2.3 Changes to Pain Processing in Injury 
Tissue damage, such as surgical incisions, can lead to neurobiological changes at multiple 
levels of the pain processing pathway that result in increased pain sensitivity, which can be 
adaptive initially but may become problematic70.  
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Peripheral sensitization 
Peripheral sensitization is described as a reduced activation threshold in peripheral 
nociceptors and increased frequency of action potentials in response to stimulation71. Tissue 
damage results in the release of endogenous molecules, known as damage associated molecular 
patterns that activate innate immune cells72. Molecules released from damaged cells can also 
directly activate nociceptors73. Activation of nociceptors and local non-neural cells results in the 
release of endogenous mediators including neurotransmitters, substance P, bradykinin, 
prostaglandin, leukotrienes, neurotropic factors, cytokines etc.74–76. Importantly, nociceptors 
express receptors for many of these molecules leading to depolarization or activation of protein 
kinases that phosphorylate transducer proteins and ion channels, resulting in sensitization20. The 
presence of these inflammatory mediators also upregulates various sodium channels in DRG 
neurons77–79. In addition, N-methyl-D-aspartate (NMDA) receptors, important in excitatory 
neurotransmission, are upregulated and phosphorylated in peripheral nociceptors during 
inflammation, increasing excitability80,81. Ultimately, the outcome is decreased firing threshold 
and an amplified response to suprathreshold stimuli.  
The substances released into the local area also: increase vascular permeability, allowing 
the escape of prostaglandins, bradykinin, growth factors and cytokines into the local area71,82,83; 
activate local immune cells that release more pro-inflammatory cytokines, chemokines, 
components of the complement cascade and vasodilators70,75,76; and they recruit circulating 
immune cells leading to an increase in immune cells at the site of injury84–86. These actions further 
increase the accumulation of inflammatory mediators at the site of damage.  
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In addition to the above mechanisms, peripheral nerve damage also induces additional 
changes leading to peripheral sensitization. Nerve damage induces changes in gene expression 
in damaged neurons which leads to changes in excitability, transduction and transmission 
properties71,87. For example, peripheral nerve injury leads to the upregulation of calcium channel 
subunits in DRG neurons which is associated with allodynia88. In addition, increased expression 
of neurotransmitters and receptors normally expressed in nociceptors are upregulated in other 
fibres resulting in a phenotypic switch with fibres that respond to light touch being recruited into 
the nociceptive circuit71,87,89,90. Nerve damage also leads to the recruitment of immune cells to 
the injured nerve and the DRG91 as well as activation of glia in the dorsal horn92,93.  
All of these changes contribute to increased spontaneous nociceptor activity, decreased 
activation thresholds, amplified response to suprathreshold stimuli and recruitment of silent 
nociceptors94. The end result is increased input to the spinal cord95.   
Central sensitization  
Peripheral tissue injury also induces changes in the central nervous system that 
contribute to increased sensitivity96. Central sensitization is associated with spontaneous activity, 
decreased activation threshold, increased responsiveness and increased receptive field size of 
dorsal horn neurons97. C fibres release glutamate, substance P, neurokinin-A and calcitonin gene 
related peptide into the dorsal horn98. The repetitive stimulation of dorsal horn neurons by C 
fibres and the substances they release trigger a range of changes in dorsal horn neurons. Firstly, 
phosphorylation and removal of magnesium block from NMDA glutamate receptors in the spinal 
cord increases their susceptibility to activation by glutamate80,99. The increased calcium entering 
the neurons strengthens the synapse between the nociceptor and the 2nd order neuron, leading 
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to hyperalgesia100. Secondly, activation of receptors for glutamate and substance P further 
increases intracellular calcium in dorsal horn neurons and leads to activation of voltage-gated 
calcium channels20,74. The increased intracellular calcium as well as binding of inflammatory and 
neurogenic mediators to neurons in the dorsal horn activates kinases that phosphorylate 
membrane channels increasing their excitability20,101. The increased responsiveness mediated by 
one kinase, phosphatidylinositol-3-kinase, is associated with phosphorylation of NMDA receptor 
subunits as well as translocation of an a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPA) subunit to the membrane in dorsal horn neurons97,102. Decreased GABA and glycinergic 
inhibitory regulation in the dorsal horn also contributes to central sensitization101,103–105. 
GABAergic and glycinergic descending projections represent a subpopulation of descending 
modulatory projections from the brain15. Increased Interferon-g (IFN-g) and Tumour Necrosis 
Factor -a (TNF-a) have both been shown to be involved in the reduction of GABA-mediated 
inhibition in the spinal cord104,106. Loss of inhibition by the descending pathways leads to 
increased transmission of excitatory nociceptive signals, including signals from low-threshold A 
fibers which may contribute to allodynia107. In addition, non-neural cells such as astrocytes, 
microglia, and T cells, are activated which triggers release of prostaglandins, cytokines (including 
Interleukin-1b (IL-1b), Interleukin-6 (IL-6), Interleukin-8 (IL-8), TNF-a) and other molecules that 
sensitize dorsal horn cells20,100,108–111. Overall, these changes result in increased synaptic strength, 
reduced activation thresholds, increased responsiveness to suprathreshold stimuli, expanded 
receptive fields and spontaneous activity in spinal cord neurons 112,113.  
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In addition to the above mechanisms of central sensitization, nerve damage also induces 
specific changes in spinal cord structures. It downregulates glutamate transporters that maintain 
glutamate levels in the synapse, leading to increased glutamate in synapses and therefore 
increased activation of glutamate receptors on neurons114. In addition, non-neural cells such as 
macrophages, neutrophils and T cells, migrate into the dorsal horn after nerve injury70,101,115. 
Nerve injury also induces proliferation of microglial cells in the spinal cord108. Microglia and 
astrocytes release cytokines and reactive oxygen species that excite spinal neurons and act in an 
autocrine and paracrine fashion creating a positive-feedback loop of pain-enhancing signals116. 
Sprouting of sympathetic neurons into the DRG and of Ab neurons into lamina II of the dorsal 
horn also contribute to increased activity of dorsal horn neurons after peripheral nerve 
injury117,118.  
Injury also induces changes in a number of supraspinal structures involved in pain 
processing119. In mice, peripheral inflammation upregulated the NR2B subunit of the NMDA 
receptor in ACC neurons and injection of an NR2B inhibitor into the ACC or systemically, inhibited 
behavioural allodynia, supporting the relevance of these changes to inflammation induced 
hypersensitivity120. Tajerian et al. (2013)121 reported global changes in DNA methylation in the 
prefrontal cortex and the amygdala after nerve injury which correlated with mechanical and 
thermal sensitivity. In addition, dendrites in the prefrontal cortex of rats subjected to spared 
nerve injury were longer and had more branches122. These changes were also accompanied by 
increased NMDA currents that were inversely correlated with paw tactile thresholds122. See Jaggi 
et al. (2011)123 or Boadas-vaello et al. (2017)124 for an in-depth review on the supraspinal changes 
induced after peripheral nerve injury and in pathological pain states.  
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2.4 Cytokines and Pain 
Cytokines are important mediators in inflammation and the many sensitizing changes 
that occur after injury such as surgery125,126. Immune cells in the area of damage, including 
macrophages or mast cells, as well as those recruited to the site of injury secrete mediators 
including cytokines127–129. Activated or damaged nerves and activated glia release neuropeptides, 
neurotransmitters and cytokines, including IL-6, TNF-a, substance P and prostaglandins, into the 
central nervous system93,127,130,131. These mediators, released from immune cells and neurons, 
act directly on nerve terminals and immune cells to modulate the inflammatory response127,128 
and neuronal sensitivity21,130. 
Some effects that alter the inflammatory response include: activating other immune cells 
like macrophages132, neutrophils75,76 and mast cells133, to release more mediators; recruiting and 
activating leukocytes via expression of adhesion molecules84–86; increasing vascular permeability 
allowing increased extravasation of other immune cells into the damaged area82,83,134; and 
inducing changes to chemotaxic signaling84,135,136.  
Direct effects on neurons by cytokines, in both the peripheral and central nervous 
system, lead to increased excitability of nociceptive pathways21,105,137,138. Cytokines trigger 
sympathetic sprouting in the DRG117; modify or change expression of ligand gated channels or 
voltage gated sodium channels in dorsal root ganglion neurons77–79,138,139; and alter inhibitory 
interneurons resulting in disinhibition of nociceptive pathways105,106. These changes lead to 
increased action potential generation and increased excitability of nociceptive pathways.   
 
14 
 
Pro-inflammatory cytokines also contribute to supraspinal changes that impact top-
down control and processing of noxious stimuli after injury. Various cytokines, including IL-1b, IL-
6 and TNF-a are increased in regions of the brain associated with pain processing, like the PAG 
and ACC, and contribute to changes in sensitivity140–142.  
The initial sensitivity mediated by the pro-inflammatory response may contribute to 
behavior aiming to protect the injured area to allow healing100. This is usually accompanied by an 
anti-inflammatory response to attenuate the disturbances and damage caused by excessive 
inflammation126. Alterations in the balance between pro-inflammatory and anti-inflammatory 
signaling is believed to be involved in the generation of increased sensitivity that outlives its 
usefulness, and which may manifest as chronic pain126.  
Given the importance of the balance between the pro-inflammatory and anti-
inflammatory responses in sensitization, higher baseline levels of pro-inflammatory cytokines or 
lower baseline levels of anti-inflammatory cytokines may predispose patients to sensitization 
before surgery or to exaggerated responses after surgery, leading to more post-operative pain. 
This project explored eight of these mediators (IFN-g, Interleukin-2 (IL-2), IL-6, IL-8, IL-10, TNF-a, 
Transforming growth factor-b (TGF-b)) and sought to determine if baseline levels, in combination 
with biomedical and psychological factors predict increased pain after BCS.  
Many different signaling pathways activated by various cytokines have been identified 
and continue to be elucidated. While cytokines are important for many homeostatic processes, 
here I will present a select review of some of the downstream effects of each of the cytokines 
investigated in this project. First, I will discuss the cells that produce each cytokine and where the 
receptors are located. Then, I will discuss some of the effects of these cells in the body, with a 
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focus on changes that lead to inflammation or sensitization. Finally, for each cytokine I will 
describe animal and human data supporting the role of that cytokine in nociception, and where 
available, the role of that cytokine specifically in post-operative pain. See Table 1 for a table 
summarizing studies on cytokines and pain in humans.  
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Table 1. Literature Review for Inflammatory Cytokines and Pain  
 Population  Sample IFN-g IL-2 IL-6 IL-8 IL-10 IL-17 TGF-b TNF-a Notes 
Acute 
Cueller et al. 
(2010)143 
Acute, unilateral knee pain 
undergoing arthroscopic ACL 
reconstruction  
(n=12, painless knee=15) 
Synovial 
fluid ­ n.s ­ n.s n.s n.s ____ n.s  
Cueller et al. 
(2009)144 
Acute, symptomatic meniscal 
tear  
(n=39, asymptomatic=31) 
Synovial 
fluid ­ ­ ­ ____ ­ ____ ____ ____ 
IFN-g and IL-6 positively 
correlated to reported pain. 
IL-8, IL-17 and TNF-a listed as 
tested but no results  
Arthritic 
Hussein et al. 
(2008)145 
Rheumatoid arthritis  
(n=24, HC =6) Serum ____ ____ ____ ____ ­ ­ ____ ­  
Liu et al. 
(2012)146 
Rheumatoid arthritis (n=18, 
HC= 18) Serum ____ ____ ­ ____ ____ ­ ____ ­ IL-17 correlated with anxiety 
Inflammatory  
Malhotra et al. 
(2012)147  
Fibromyalgia  
(n=26, HC = 26) Plasma ¯ ¯ ­ ____ ¯ ____ ____ _____ 
IL-2, IL-10 and IFN-g negatively 
correlated with VAS score. 
IL-6 positively correlated with 
VAS score. 
Mendieta et al. 
(2016)148 
Fibromyalgia  
(n=15, HC=14) Serum UD UD ­ ­ UD ____ UD ____ 
IL-6 and IL-8 correlated with 
fibromyalgia impact 
questionnaire score 
Wang et al. 
(2008)149 
Fibromyalgia  
(n=20, HC= 80) Serum ____ ____ n.s ­ ____ n.s ____ ­ 
IL-8 correlated with VAS at the 
end of treatment 
Üçeyler et al. 
(2006)150  
Chronic widespread pain  
(n=40, HC= 40 ) 
Serum ____ ____ ____ ____ ¯ ____ n.s n.s This population included 26 
patients with fibromyalgia mRNA ____ n.s ____ n.s ¯ ____ n.s n.s 
Lundh et al. 
(2013)151 
Chronic prostatitis-chronic 
pelvic pain syndrome  
(n=32, HC=37) 
Plasma ____ n.s ____ ____ ____ ____ ____ ­ 
TNF-a only significant when 
controls with health problems 
removed 
17 
 
Inflammatory Cont’d Sample IFN-g IL-2 IL-6 IL-8 IL-10 IL-17 TGF-b TNF-a Notes 
Miller et al. 
(2002)152 
Chronic prostatitis-chronic 
pelvic pain syndrome  
(n=48, HC=14) 
Seminal 
plasma ­ n.s ____ n.s ­ ____ ____ ____ 
IL-10 correlated with positively 
with pain intensity 
Slade et al. 
(2011)153  
Temporomandibular 
disorders w/ widespread 
palpation tenderness (WPT) 
vs without  
(n=84, no WPT= 115) 
Plasma UD UD n.s ­ UD UD ____ n.s  
Neuropathic 
Alexander et al. 
(2012)154 
Complex regional pain 
syndrome 
(n=148, HC=60) 
Plasma ­ ­ n.s ­ n.s ____ ____ ­  
Üçeyler et al. 
(2007)a155 
Complex regional pain 
syndrome  
(n=42, HC=34) 
Serum ____ ­ ____ n.s ¯ ____ ¯ n.s  
Backonja et al. 
(2008)156 
Chronic pain from post-
traumatic neuralgia or distal 
painful non-diabetic 
polyneuropathy  
(n=14, HC=6) 
Plasma ____ ____ n.s n.s ¯ ____ ____ n.s  
IL-10 inversely correlated with 
pain intensity 
Bäckryd et al. 
(2016)157 
Chronic peripheral 
neuropathic pain  
(n=14, HC= 17) 
Plasma ____ ____ ­ n.s ____ ____ ____ UD Mostly failed back surgery associated radiculopathy 
Pedersen et al. 
(2015)158  
Lumbar radicular pain 
secondary to disc herniation, 
severe VAS³3 vs mild pain 
VAS<3 
(severe n=52, mild n =75) 
Serum ____ ____ ­ ­ ____ ____ ____ ____ IL-6 and IL-8 associated with pain intensity score on VAS 
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  Sample IFN-g IL-2 IL-6 IL-8 IL-10 IL-17 TGF-b TNF-a Notes 
Wang et al. 
(2016)159 
Severe (VAS >3) sciatica pain 
secondary to lumbar disc 
herniation vs mild VAS (£ 3)  
(n=58, mild = 50) 
Serum ____ ____ ­ n.s ¯ ____ ____ ­  
Severe (VAS>3) sciatica pain 
secondary to lumbar disc 
herniation vs HC (n=58, 
HC=30) 
Serum ____ ____ ­ ­ n.s ____ ____ ­ IL-10 was increased in mild sciatica compared to HC 
Üçeyler et al. 
(2007)b160 
Painful vs. painless 
neuropathy  
(painful n=32, painless =20) 
Serum ____ ­ ____ ____ n.s ____ ____ ­  
Üçeyler et al. 
(2010)161 
Small fibre neuropathy (n=24, 
HC=34) 
mRNA in 
blood ____ ­ n.s n.s ­ ____ ­ n.s 
 
Mixed  
Koch et al. 
(2007)162  
Chronic neuropathic, 
nociceptive or mixed pain 
(n=94, HC=6) 
Plasma n.s n.s ­ n.s n.s ____ ____ n.s 
IL-2 and TNF-a elevated in 
patients with severe (NRS=7-
10) vs. light pain (NRS=1-3) but 
only severe pain above level of 
sensitivity 
Post-operative  
Ko et al. 
(2018)163 
Hip fracture surgery in pts >60 
yrs of age (n=40) 
Correlation with POD 3 
resting pain and walking pain 
Plasma ____ ____ n.s ____ ____ ____ ____ ­  
Si et al. 
(2017)164 
Patients undergoing total 
knee arthroplasty (n=96) 
Correlation with NRS-R and 
NRS-M pre and 24-hrs post-op 
Serum ____ ____ ­ n.s ____ ____ ____ n.s 
IL-6 also significantly 
associated with NRS-M 48 and 
72 hrs post-op.  
Other 
Dennis et al. 
(2014)165 
Opioid addicted patients with 
comorbid pain vs. without  
(with pain n=58, no pain=177) 
Serum ­ ___ n.s n.s n.s ___ ____ n.s IFN-g only significant after adjusting for covariates 
ACL: anterior cruciate ligament. HC: healthy controls. IFN-g: Interferon-g. IL- 2: Interleukin-2. IL-6: Interleukin-6. IL-8: Interleukin-8. IL-10: Interleukin-10. IL-17: 
Interleukin-17. mRNA: Messenger Ribonucleic Acid. n.s: not significant. NRS-R: Numeric Rating Scale at rest. NRS-M: numeric rating scale with movement. TGF-
b: Transforming Growth Factor-b. TNF-a: Tumour Necrosis Factor-a. UD: undetectable. VAS: visual analog scale. WPT: widespread palpation tenderness
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Pro-nociceptive 
Interferon-g 
IFN-g is produced primarily by T cells166,167, including both cytotoxic T cells168,169 and T 
helper cells166, and natural killer (NK) cells167,170–172. It is also produced by astrocytes173 and 
neurons173,174. There are two subunits that make up the IFN-g receptor: IFN-gR1 is expressed on 
all cells175. IFN-gR2 is expressed at very low levels on all cells but can be induced175 allowing the 
effect of IFN-g to be closely regulated. Importantly, DRG neurons express both subunits174,176, and 
receptors in the dorsal horn are most dense in the superficial layers, the location of nociceptive 
pathways176,177, suggesting a direct effect on nociception is likely.  
IFN-g has diverse effects on different cell types. On macrophages, IFN-g induces the 
release of IL-1, IL-6, TNF-a178, reactive oxygen intermediates and reactive nitrogen 
intermediates179, which increase the inflammatory response. On monocytes it induces 
complement protein production180 and activates tumoricidal activity181. However, it also induces 
IL-10 production182 and inhibits IL-8 production from monocytes, effects which may counter the 
inflammatory response.  
In addition, IFN-g activates NK cells which further increases IFN-g release183. On the other 
hand, it inhibits proliferation of TH2 cells and production of IL-4 and IL-5 by TH2 cells184. Additional 
control of the inflammatory response is generated by IFN-g mediated inhibition of IL-17 release 
from T helper cells185.  
Effects on neutrophils are also diverse. IFN-g increases phagocytosis, increases reactive 
oxygen species production, increases release of enzymes from granules and increases TNF-a and 
IL-6, all pro-inflammatory effects75. However, evidence for its effect on neutrophil recruitment is 
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mixed and may suggest complex regulation. IFN-g inhibits IL-8 production (chemokine for 
neutrophils)186 and some reports indicate IFN-g limits neutrophil recruitment185, which would 
limit inflammation. Others, however, have found it is necessary for neutrophil attraction136,187. 
Bonville et al. (2009)187 suggested it was not sufficient to recruit neutrophils but was required in 
combination with another cofactor.  
Although the effects on neutrophils are unclear, IFN-g does play a role in the recruitment 
of other immune cells. It increases cell surface adhesion molecules, such as intercellular adhesion 
molecule 1 (ICAM-1), and antigen presentation molecules on keratinocytes135. It also induces 
keratinocytes to release chemokines including monocyte chemotactic protein-1 (MCP-1) 
(attracts monocytes, dendritic cells and T cells), and RANTES, which attracts T cells135.  
In addition to effects on a range of immune cells, IFN-g is involved in signaling in the 
nervous system and is upregulated in the dorsal horn after nerve injury115. IFN-g increases 
spontaneous activity in dorsal horn neurons and increases after-discharges188 which may occur 
in part due to reduced GABA mediated inhibition104. It also directly induces neuronal dysfunction 
by enhancing glutamate neurotoxicity via changes to AMPA receptors that lead to increased 
calcium influx which upregulates nitric oxide synthase189. The hyperresponsiveness may also be 
related to increases in NMDA-induced currents190.  
Spinal-glial cell interactions also play a role in IFN-g mediated hypersensitivity. IFN-g 
activates microglia and astrocytes189 and increases proliferation of microglia108. Activation by IFN-
g upregulates nitric oxide synthase which increases production of nitric oxide in glial cells191 and 
increases cell surface adhesion molecules on microglia, such as ICAM-1 and vascular cell adhesion 
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molecule (VCAM-1)192. Activated microglia also release mediators that increase NMDA-induced 
currents on neurons, increasing reactivity of neurons in the substantia gelatinosa190. 
These diverse effects mostly serve to increase the inflammatory response and immune 
reaction at the site of injury and in the nervous system. The molecular mechanisms outlined 
above support an hypothesis regarding how IFN-g may increase pain sensitivity after surgery. The 
pro-nociceptive effect of this cytokine is further supported by animal models. In knockout mice 
lacking IFN-gR1, mechanical allodynia after nerve injury was significantly reduced suggesting 
signaling through this pathway was essential for development of the neuropathic pain 
phenotype115. In addition, activation of the IFN-g receptor on microglia induced tactile allodynia 
in rats, while ablating the receptor reduced allodynia108. Furthermore, intrathecal administration 
caused mechanical allodynia and hyperalgesia108,188.  
Human studies have also supported the role of this cytokine in pain processes. IFN-g was 
elevated in the plasma of patients with complex regional pain syndrome (CRPS)154 and a 
reduction in IFN-g predicted a reduction in NeP in spinal cord injury patients193. In addition, it was 
elevated in patients with comorbid opioid addiction and pain compared to patients with opioid 
addiction but no pain165. It was also elevated in the seminal plasma of patients with chronic 
prostatitis-chronic pelvic pain syndrome152. On the other hand, IFN-g in the plasma of patients 
with chronic nociceptive, neuropathic or mixed pain was not different from controls162. The 
heterogenous nature of the patient population in that study may have contributed to this 
discrepancy162. Interestingly, one study of patients with fibromyalgia reported a decrease in 
patients compared to healthy controls147, however, a systematic review of cytokines in patients 
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with fibromyalgia compared to healthy controls found no difference in serum or plasma IFN-g, 
although this included only two studies194.  
In the acute setting, in the synovial fluid of patients with acute knee pain undergoing 
anterior cruciate ligament reconstruction143 or with symptomatic meniscal tear144 IFN-g was 
elevated relative to controls. There were few studies assessing IFN-g in surgical settings. One 
study found non-neurological surgery did not correlate with a change in IFN-g concentration 
compared to baseline but this study did not investigate pain195. In addition, IFN-g was not 
increased in the serum of patients after orthopaedic trauma compared to healthy controls196. 
The lack of a response after surgery or trauma could be related to the time frame at which the 
effect was measured. Regardless, the involvement elucidated by molecular studies, animal 
studies and some human chronic and acute pain studies, suggests that baseline levels of IFN-g 
could assist in identifying those at increased risk of sensitization and increased pain after BCS.  
I was unable to identify any studies investigating IFN-g concentrations in patients 
undergoing BCS. One study identified a short nucleotide polymorphism (SNP) in the gene for IFN-
g increased the risk of severe persistent pain after BCS197 however, how this polymorphism 
impacts concentrations is unclear making conclusions difficult to draw. 
While there is some conflicting evidence, IFN-g clearly plays a significant role in 
inflammatory processes and in nociception and the balance of studies suggest it is pro-
nociceptive. A better understanding of whether systemic levels of IFN-g can predict for pain after 
BCS is warranted.  
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Interleukin-6  
IL-6 is a 22-27kDa glycoprotein that can be produced by nearly all cell types125 including 
immune cells such as macrophages198, monocytes199, T cells200, B cells201, neutrophils75,202, 
dendritic cells203, basophils and mast cells204. Cells in the nervous system such as neurons205, 
specifically DRG neurons206 and sympathetic neurons207, and glial cells206, also produce IL-6 
providing a local source to effect changes in the nervous system. Non-immune cells such as 
hepatocytes208, fibroblasts209, endothelial cells210, epithelial cells211, and adipocytes212 also 
contribute. Importantly, breast stromal cells secrete IL-6, and this may be altered in malignant 
breast tumors213, although results have been mixed as to whether local IL-6 is protective or 
harmful in malignancy214. Serum levels in patients with breast cancer have consistently been 
shown to be elevated compared to controls, with levels associated with stage of disease214. In 
the current study, this could increase the risk of post-operative pain in patients with more 
significant or advanced disease prior to surgery.  
There are two subunits to the IL-6 receptor complex, IL-6R and gp130215,216. The gp130 
subunit, the signal transduction portion, is expressed on all cells215,216, including on DRG neurons 
and glial cells206. The IL-6R component, which has a more limited expression pattern, exists as a 
membrane bound receptor and in a soluble form216. Membrane bound IL-6R is found on 
hepatocytes, monocytes217, macrophages218 and some lymphocytes219. It is also expressed on 
epithelial cells211 and breast adipocytes212. In the nervous system, some have reported 
expression of IL-6R on neurons206 while others have not found neural expression220,221. Microglia 
also express IL-6R218,222 and astrocytes express IL-6R mRNA but no protein218. Cells that do not 
express the membrane bound version require soluble IL-6R in order to respond to IL-6. The 
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soluble receptor is released by cleavage of the membrane bound form223 or by alternative 
splicing224.  
IL-6 binds either membrane bound IL-6R or soluble IL-6R, which then associates with 
gp130225, triggering dimerization and the initiation of signaling226. Signaling via the soluble IL-6R 
is thought to be predominantly responsible for the pro-inflammatory227 and the 
neuropathological effects of IL-6228.  
As a result of the widespread expression of both IL-6 and its receptors, and the ability of 
cells to respond to IL-6 in the presence of the soluble form of IL-6R, this cytokine has extensive, 
pleiotropic effects. Firstly, it contributes to the acute phase response229 and angiogenesis230, 
suggesting it would be important in the immediate post-operative reaction and in healing.  
IL-6 also promotes TH2 and TH17 differentiation and inhibits TH1 differentiation and T 
regulatory (Treg) cell generation231,232. Importantly, Treg cells are primarily responsible for 
dampening the immune response, so inhibition of Treg cell differentiation increases 
inflammation and the immune response232. IL-6 also contributes to T follicular helper cell 
induction and expansion201. In cytotoxic T cells, it increases development of effector functions, 
including release of TNFa and IFN-g, two pro-inflammatory cytokines111.  
IL-6 also induces monocyte differentiation to macrophages233. Interestingly, it induces 
macrophage production of IL-1R antagonists (IL-1Ra) and soluble TNFa receptors, which dampen 
the inflammatory response234, likely a mechanism to prevent damage from too great an 
inflammatory response.  
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IL-6 increases neutrophil proliferation235 but inhibits neutrophil recruitment236. IL-6 is 
involved in the recruitment of leukocytes237 and researchers have suggested it is involved in the 
switch from the initial neutrophil immune response to a more robust leukocyte response238. It 
recruits leukocytes by increasing ICAM-1 on endothelial vessels and increasing the expression of 
the chemokines MCP-1 and IL-8 from peripheral mononuclear cells84. It also increases MCP-1 
from endothelial cells84. Some have shown IL-6 reduces expression of IL-8 from endothelial cells, 
but this is debated84,239. IL-6 also increases chemokine receptor expression on T cells240 further 
assisting with recruitment of immune cells that increase the inflammatory response at the site of 
injury. Increased concentration of IL-6 systemically may therefore increase the inflammatory 
response during and after surgery.  
In the nervous system, IL-6 activates microglia increasing inducible nitric oxide synthase 
mRNA109 and expression of TNF-a in microglial cells93, increasing inflammatory mediators locally 
within the nervous system. IL-6 also directly affects neurons in a number of ways. It increases 
intracellular calcium in DRG neurons acutely and increases neurokinin-1 receptors in DRG 
neurons after extended exposure137. It also alters voltage gated and receptor operated ion 
channels in various neural subsets, with some changes resulting in hyperexcitability and others 
having neuroprotective effects (see Vezzani & Viviani (2015)138 for a review). IL-6 generates 
hyperexcitability in dural neurons by increasing a voltage gated sodium channel (Nav 1.7)241. IL-6 
also increases transient receptor potential vanilloid- 1 receptor (TRPV1, responsible for heat 
sensitivity) in DRG neurons, which also increases excitability79. gp130, the signal transducer for 
IL-6 is required for expression of the transient receptor potential ankyrin-1 channel (TRPA1, 
important for chemical and mechanical sensitivity), so IL-6 signalling may also be involved in the 
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upregulation of this channel242. These changes may explain the heat sensitization in spinal 
neurons and mechanical sensitization of C-fibres reported with increased IL-6 or IL-6 treatment 
221,243. IL-6 also reduces GABA-induced currents by changes in lamina II of the spinal cord105 and 
in the PAG of the brain140, leading to disinhibition and increased excitability. All of these changes 
in ion channels result in increased excitability of neurons and therefore increased susceptibility 
to hyperalgesia. In addition, IL-6 induces sympathetic sprouting, with sympathetic fibres invading 
into the DRG, an effect that leads to cross-talk between the two systems117.  
On the other hand, IL-6 promotes neuronal survival207,244,245. For example, it can reduce 
the number of sodium channels in spinal cord neurons, reducing excitatory currents and 
protecting neurons by decreasing release of excitatory transmitters or by reducing energy 
consumption244. This has been proposed as a compensatory neuroprotective mechanism138. 
Although, IL-6 has a positive effect on neuronal survival and differentiation, its involvement in 
the physiology of nociception, suggests it may be an important mediator contributing to the post-
operative pain experience245.  
In animal studies, IL-6 was increased in the DRG205 and the spinal cord246 after nerve 
injury, and this increase was associated with mechanical allodynia247. In addition, IL-6 knockout 
mice had reduced hyperalgesia and reduced plasma extravasation in response to an 
inflammatory stimulus suggesting a reduced inflammatory response83. Exogenous application of 
IL-6 via intraplantar injection in rats also caused hyperalgesia and injection of an IL-6 antibody 
attenuated this response248. Administration of an IL-6 antibody also delayed the nerve-injury-
associated mechanical allodynia, supporting the role of IL-6 in the development of nerve-injury-
related allodynia247. All of these studies suggest IL-6 is an important mediator of the behavioural 
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outcomes of both inflammatory and nerve injury related stimuli. As such, IL-6 is also likely 
important in the response to surgery, which includes both an inflammatory response249,250 and 
potential nerve damage6.  
Studies in humans have also largely supported the pro-nociceptive effects of this 
cytokine. Most studies comparing patients with chronic pain to healthy controls have reported 
increased IL-6, including in patients with chronic peripheral neuropathic pain157; chronic 
nociceptive, neuropathic or mixed pain162; rheumatoid arthritis146, and fibromyalgia147,148. In 
addition, a meta-analysis reported higher plasma IL-6 in patients with fibromyalgia compared to 
controls194. IL-6 was also positively correlated with pain intensity in patients with chronic pain 
receiving long-term intrathecal opioids251. Furthermore, it was found to be elevated in patients 
with more severe lumbar radicular pain secondary to disc herniation compared to those with less 
pain158,159 or healthy controls159.  
Conversely, however, IL-6 was not associated with comorbid pain in patients with opioid 
addiction 165 and no difference was found in patients with chronic post-traumatic neuralgia or 
distal painful non-diabetic polyneuropathy compared to healthy controls156. There was also no 
difference reported in patients with temporomandibular joint disorder with widespread 
palpatory tenderness compared to those without widespread palpatory tenderness153 or 
between patients with CRPS and healthy controls154. These differences could be related to 
different time points within a disease process, as reflected in the wide range of disease duration. 
For example, Backonja et al. (2008)156 examined patients a mean of 10 years (range .8-20.2) after 
disease onset and Alexander et al. (2012)154 examined patients a mean of 8.8 years (range .7-36) 
after disease onset. Both of these studies found no difference in IL-6 in patients compared to 
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controls. On the other hand, Pedersen et al. (2015)158 examined patients 6 weeks and 12 months 
after disease onset, and Wang et al. (2016)159 examined patients with mild sciatica on average 23 
weeks after disease onset and patients with severe sciatica on average 48 weeks after disease 
onset. Both of these studies reported significant differences between severe pain and mild pain. 
Another study found increased serum IL-6 levels after disc herniation predicted increased 
disability at 1 year252 supporting the importance of IL-6 levels in the acute or early period 
following disease onset or injury. A study by Bäckryd et al. (2016)157 examined patients on 
average 7.8 years after disease onset and found increased IL-6 in patients however, they did not 
exclude patients with other painful comorbidities which may have affected IL-6 levels. Despite 
discrepant findings, overall IL-6 seems to be involved in chronic pain, especially in the early period 
after disease onset, suggesting it could be effecting changes in the nervous system that increase 
sensitivity to pain.  
Consistent with this, elevations in IL-6 have also been reported in acute pain. Plasma IL-
6 was positively correlated with pain qualities in a study of older women with acute low back 
pain253. It was also elevated in knee synovial fluid in patients with acute, symptomatic meniscal 
tears144 and acute, painful anterior cruciate ligament tears143 compared to non-injured knees.  
Studies on IL-6 in post-operative pain are limited. However, IL-6 is considered a marker 
of the extent of tissue damage after trauma254 and surgical procedures255. It is increased after 
abdominal surgery256. Interestingly, this increase was delayed and exaggerated in older patients 
compared to young adult patients256. In a study on total knee arthroplasty, serum IL-6 was 
positively correlated with resting and movement-related pain intensity pre-operatively and 24 
hours after surgery164. Serum IL-6 in this study continued to be correlated with movement related 
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pain intensity three days post-operatively164. IL-6 was also locally elevated after surgical 
extraction of impacted third molars and levels correlated with pain intensity257. It was not 
however, associated with pain after acute hip fracture surgery in patients >60 years old163. This 
study had a small sample size (n=40) and only measured IL-6 three days after surgery which may 
not have captured the early effects of IL-6 on post-traumatic sensitization. Although IL-6 
continued to be associated with walking pain three days after total knee arthroplasty, these 
patients had severe arthritis, a progressive chronic condition258, while patients undergoing hip 
surgery had an acute condition163, therefore the subsequent inflammatory responses may have 
differed. Only one study was available on BCS patients. This study identified an SNP in the gene 
for IL-6 that decreased the risk of mild persistent pain after BCS259. This gene is associated with 
lower serum levels of IL-6 protein259, suggesting lower levels of IL-6 could be protective in the 
post-operative period. The potential protective effect of lower serum levels of IL-6 suggests 
exploring how baseline levels of IL-6 could affect sensitization processes before surgery or the 
degree of inflammatory response to surgery is warranted.  
In addition to the above studies on both chronic and acute IL-6 in human pain, an 
examination of immunotherapy for painful inflammatory conditions further supports the 
involvement of IL-6 in pain processes. A review of therapeutics targeting cytokines found 
intrathecal administration of IL-6 neutralizing antibody reduced mechanical allodynia and an IL-
6 neutralizing antibody is currently in use for patients with rheumatoid arthritis260. This anti-
human IL-6R antibody, Tocilizumab, reduced the number of tender and swollen joints and 
improved health-related quality of life in patients with rheumatoid arthritis261. Case reports on 
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this neutralizing antibody have described reduced pain in other conditions including sciatica260, 
further supporting the importance of this cytokine in pain conditions.  
The balance of the findings on the role of IL-6 at the cellular level, the increases found in 
both animal and human pain studies, and the effect of anti-IL-6 immunotherapy suggest IL-6 
could be an important mediator in increasing risk for post-operative pain after BCS. This study 
explored whether IL-6, in combination with other risk factors, could identify patients at elevated 
risk for significant acute post-operative pain 
Interleukin 8  
IL-8 is a chemotactic cytokine involved in inflammation and nociception112. It is produced 
by a wide range of cell types including monocytes262, endothelial cells263, lymphocytes264, 
fibroblasts265, epithelial cells266, keratinocytes267, and microglia 222,268. Receptors for IL-8 include 
CXCR1 and CXCR2269 and are expressed on immune cells including neutrophils270, monocytes271, 
T cells169,272, mast cells273, basophils274, NK cells275 and microglia222. Neurons in the substantia 
gelatinosa also express a receptor for IL-8276. 
IL-8 attracts neutrophils277,278 and T cells to the site of damage272. In neutrophils, 
activation by IL-8 leads to degranulation, releasing enzymes and more chemotactic molecules76. 
Activation of mast cells by IL-8 results in cell migration273. IL-8 also regulates expression of 
leukocyte adhesion molecules on endothelial cells86, facilitating the recruitment of leukocytes to 
the site of injury. These effects increase the presence of other immune cells at the site of injury, 
leading to increased accumulation of inflammatory factors that could influence pain.  
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Increased IL-8 in animal models supports the association between IL-8 and inflammation 
and nociception. IL-8 was increased in the DRG and dorsal horn in an animal model of lumbar 
disc herniation and intrathecal administration of an IL-8 receptor antibody reduced associated 
mechanical allodynia, supporting the importance of IL-8 signaling in the development of 
allodynia279. IL-8 was also increased in the spinal cord and ACC in an animal model of 
inflammatory pain142. In the ACC, IL-8 increased synaptic transmission, via both pre and post-
synaptic mechanisms and blocking IL-8 with an antibody reduced the observed excitability as well 
as thermal hyperalgesia142. These studies of both a nerve injury model and an inflammatory pain 
model support the direct role IL-8 has on the excitability of neurons and on nociception. This 
suggests IL-8 could play an important role in pain after surgery, which could include both nerve 
injury6 and inflammatory signals249. 
Human studies have demonstrated mixed results on the association between IL-8 and 
chronic pain. Increased IL-8 in fibromyalgia148,149 and CRPS154, compared to healthy controls, 
supports the pro-nociceptive effect of IL-8. In addition, patients with temporomandibular joint 
disorders and widespread palpatory tenderness had increased plasma IL-8 compared to those 
without widespread palpatory tenderness153. IL-8 was also increased in patients with more 
severe (visual analog scale (VAS)³ 3) lumbar radicular pain secondary to disc herniation 
compared to those with less pain (VAS<3)158. Wang et al. (2016)159 however, found increased IL-
8 in patients with lumbar radicular pain due to disc herniation compared to healthy controls but 
not compared to patients with less severe pain (£3). The reasons for the discrepant results in two 
studies investigating similar conditions is unclear, however, different cut-offs for mild and severe 
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pain were used and other methodological differences may have contributed. Regardless, IL-8 
seemed to be involved in the pathology of this neuropathic condition. 
Others have also reported no difference in IL-8 levels in patients with chronic pain 
conditions compared to healthy controls152,155–157,162,165. These differences could be related to a 
range of methodological dissimilarities between studies, such as inclusion criteria, and small 
sample sizes194. In addition, due to the chemotactic nature of the effects of IL-8, systemic levels 
may not be as informative as local levels155,277.  
Minimal human research has been completed investigating IL-8 and acute pain. A study 
on acute pain secondary to anterior cruciate ligament tear found no increase in IL-8 in synovial 
fluid from painful knees143. This study found increases in other chemotactic proteins including 
MCP-1. It is possible that in this specific condition, other chemotactic molecules are more 
important than IL-8 whereas, in other conditions IL-8 is a more important chemotactic molecule.  
Despite these mixed results in chronic and acute human pain conditions, IL-8 may be 
involved in immune and inflammatory responses after surgery. IL-8 was increased in response to 
lower abdominal surgery256, and the molecular mechanisms outlined above could affect 
subsequent pain experiences. The influence of IL-8 on post-surgical pain has been investigated in 
the local environment after impacted third molar extraction, where it was increased and 
correlated with pain intensity257. In another study however, serum IL-8 after total knee 
arthroplasty was not associated with resting or movement related pain164. No studies exploring 
IL-8 levels and post-BCS pain were identified, however one study found there was no association 
between 3 different SNPs of the IL-8 gene with severe pain after BCS197. This study however, did 
not investigate cytokine concentrations making it unclear if other mechanisms, aside from 
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genetic polymorphisms, such as post-translational changes, could influence IL-8 concentrations 
and post-BCS pain.   
Notwithstanding some conflicting evidence, given the role of IL-8 in propagation of the 
inflammatory response and in sensitization, and the finding that IL-8 is increased after 
surgery250,256, this study examined whether baseline levels are a risk factor for increased post-
operative pain.  
Interleukin-17  
IL-17A is the prototypical cytokine in the IL-17 family. Some research specifies IL-17A 
while other studies report on IL-17, without specifying which member of the family. Although IL-
17A was measured in this study, evidence regarding IL-17A and IL-17 will be reported here.  
IL-17A is a 17-26 kDa protein with variable levels of glycosylation280. It is predominantly 
produced by TH17 cells281–283, however, others have shown that gd T cells284, invariant natural 
killer T cells285, lymphoid tissue inducer-like cells286, neutrophils283, B cells287, microglia192, and 
astrocytes81,288 are also able to produce IL-17.  
The IL-17RA receptor is made up of two subunits: IL-17RA and IL-RC289,290. IL-17R is 
expressed ubiquitously on all cells that have been tested in various studies including B cells, NK 
cells, peripheral blood mononuclear cells, endothelial cells, epithelial cells and fibroblasts280,290–
294. Some have identified IL-17RA on C fibres in the DRG295 and spinal neurons81 while others have 
reported that IL-17 receptors are found on astrocytes and microglia but not on neurons192. 
Regardless, some direct effect on cells of the nervous system is likely.  
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IL-17 stimulates secretion of inflammatory mediators including IL-6, IL-8, granulocyte 
colony stimulating factor (G-CSF), prostaglandin E2 (PGE2), and adhesion molecules from synovial 
fibroblasts296; induces transcription of TNF-a and secretion of cytokines including TNF-a, IL-6, 
and PGE2 from macrophages110; induces IL-8 synthesis and release from epithelial and 
endothelial cells297; and increases production of nitric oxide and inducible nitric oxide synthase 
from chondrocytes298. IL-17 also stimulates granulopoiesis299 and stimulates T cells to 
proliferate280. In addition to the above molecules directly increasing inflammation, the above 
changes also recruit neutrophils283,292,300, macrophages and T cells294,300.  
IL-17 also affects CNS cells. It induces microglia to produce neurotropic factors such as 
nerve growth factor, IL-6 and adhesion molecules192, leading to the accumulation of immune cells 
and inflammatory mediators that contribute to sensitization100. In addition, IL-17A activates 
signalling cascades resulting in phosphorylation of protein kinase B and ERK in C fibres, which 
alters voltage gated ion channels enhancing excitability295. Meng et al. (2013)81 postulated that 
hyperexcitability of nociceptive neurons is mediated through IL-17 dependent phosphorylation 
of NR1, part of the NMDA receptor, on neurons.  
The molecular changes induced by IL-17 result in an enhanced inflammatory response 
and sensitization of neurons. Data from animal models suggests that these molecular changes 
lead to pro-nociceptive changes. IL-17 was increased in injured nerves300 and in astrocytes in the 
DRG after an inflammatory stimulus81, and the elevated IL-17 resulted in increased mechanical 
allodynia and reduced withdrawal thresholds81,300. In addition, IL-17 deficiency decreased 
hypersensitivity normally observed after nerve injury300 and local injection of IL-17 antibody 
reduced hyperalgesia81. These findings further support the involvement of IL-17 in both 
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neuropathic and inflammatory pain. Given that surgery causes tissue damage that induces 
inflammation249 and may cause nerve damage6, IL-17 could contribute to the mechanism behind 
post-operative pain.  
Despite evidence for the role of IL-17 in pain processes, human research on IL-17 has 
been limited and focused primarily on autoimmune disorders, including those with pain as one 
of the primary symptoms such as rheumatoid arthritis. IL-17 was elevated in patients with 
rheumatoid arthritis compared to controls145,146; and a meta-analysis further supported this 
finding301. One study in a non-autoimmune population found IL-17 was elevated in patients with 
intervertebral disc degeneration compared to healthy controls, and IL-17 levels correlated with 
reported pain302. It was however, not elevated in fibromyalgia patients compared to healthy 
controls149. Given the limited number of studies in chronic pain conditions, it is difficult to draw 
conclusions about the effect of IL-17 on pain processes outside of autoimmune conditions like 
rheumatoid arthritis.  
In addition, the only study on acute pain that was identified demonstrated no significant 
difference in IL-17 in the synovial fluid drawn from the symptomatic knee of people with acute 
knee pain secondary to anterior cruciate ligament tear compared to the asymptomatic knee or 
healthy controls143. No studies examining the effect of IL-17 on post-operative pain or post-BCS 
pain were identified. Despite limited evidence in human pain populations, the role of this 
cytokine on propagating the immune response and its direct effect on nociceptors, suggest an 
increased basal level of IL-17 could predispose patients to greater inflammatory responses and 
increased pain after surgery. A better understanding of the role of this cytokine in pain is needed 
and this study investigated whether baseline IL-17 levels contribute to post-BCS pain.  
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Tumour Necrosis Factor - a 
TNF-a is another pro-inflammatory cytokine that has been implicated in pain processes 
and is an early mediator in the inflammatory response after surgical procedures, trauma or 
infection125,303. TNF-a exists as a 26 kDa transmembrane molecule as well as a soluble 17 kDa 
molecule304. It is produced by a wide range of cells including monocytes305 and 
macrophages132,306, dendritic cells306, T cells307,308, mast cells309, endothelial cells, fibroblasts132, 
synoviocytes305,310 and supportive cells in the nervous system including glia311 and Schwann 
cells132. TNF-a does not appear to be produced by neural cells and production in the DRG seems 
to be limited to non-neural cells306.  
There are two receptors for TNF-a, TNFR1 and TNFR2. Receptors are found on all 
nucleated cell types312, including on immune cells126. The distribution of these receptors in the 
nervous system is debated. Some report expression of both TNFR1 and TNFR2 in DRG neurons313–
316, while others have found TNFR1 only on neural cells, and both TNFR1 and TNFR2 on non-
neuronal cells in the DRG91,306. TNFR1 on primary sensory neurons may be primarily responsible 
for effects on nociception317–319. TNFR2 is expressed on Treg cells and may have an anti-
inflammatory effect to prevent overactivation of inflammatory responses320. TNF-a signalling 
through TNFR1 upregulates TNFR2310. An upregulation of both receptor types has been observed 
after nerve injury321 and in inflammatory models91,306.  
This cytokine’s sensitizing effect is mediated via both direct and indirect mechanisms. 
Indirect effects lead to increased concentrations of other cytokines and an accumulation of 
inflammatory mediators. TNF-a induces IL-6 which activates PGE2 synthesis248. It also increases 
release of IL-8265, nerve growth factor and IL-1b, other factors involved in propagating the 
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immune response and sensitization322. TNF-a increases vascular permeability82, in part by 
upregulating vascular cell adhesion molecule-1134 and E-selectin236, allowing infiltration of 
macrophages91 and neutrophils to the injury site309. In addition, TNF-a signalling activates glial 
cells which contribute to inflammation by releasing other mediators116,191.  
Not only does TNF-a increase immune cells and inflammatory mediators at the site of 
injury, but direct effects on neurons are also widespread. TNF-a signalling results in changes to a 
number of ion channels in neurons. Upregulation of Nav1.777, Nav1.378 and Nav1.878,139 in A and 
C fibre DRG neurons occurs in response to TNF-a. AMPA receptors are also inserted into neuronal 
membranes323 and an increase in the number of DRG neurons expressing TRPV1, a channel that 
mediates thermal hyperalgesia, has also been reported315. In addition, TNF-a inhibits tonic firing 
of inhibitory interneurons in lamina II106. These changes result in increased responsiveness of C 
fibres82,313,324 and ectopic activity82,324. Furthermore, TNF-a triggers the release of intracellular 
calcium stores and activates stress kinases in sensory neurons314. It is also involved in activating 
sympathetic tone observed in inflammatory states325.  
The effects of TNF-a in the peripheral and central nervous system are widespread but 
include indirect effects on immune cells that result in upregulation of various inflammatory 
mediators involved in enhancing neuronal sensitivity as well as direct actions on neural cells. 
Ultimately, TNF-a initiates changes in the peripheral and central nervous systems that could pre-
sensitize individuals to increased pain after surgery. A higher baseline level could also result in an 
increased response to an insult such as surgery.  
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The connection between the changes observed in molecular studies with behaviour has 
been demonstrated in animal models. Animal models have demonstrated that TNF-a is 
upregulated after nerve injury132, in both injured neurons and neighbouring intact neurons326. 
Increased TNF-a locally in inflamed skin327, in non-neural DRG cells306 and in cerebrospinal fluid304 
after inflammation has also been reported. In addition, increased TNF-a after an inflammatory 
stimulus was associated with hypernociception in mice and TNFR1 knockout mice displayed 
reduced hyperalgesia to inflammatory stimuli327 supporting the importance of this cytokine in 
the behavioural response to inflammation. Furthermore, administration of exogenous TNF-a led 
to increased firing in sensory afferent fibres324, hyperalgesia322,327–329 and mechanical allodynia329 
in both rat and mice models. The increased TNF-a observed after nerve or inflammatory injury 
and association with hyperalgesia suggest this is an important mediator of pain responses after 
injury and thus, could be important in post-operative pain.  
While molecular studies and animal models support the involvement of TNF-a in the 
response to injury, further evidence for the involvement of TNF-a in pain processes comes from 
studies on chronic pain patients. TNF-a was elevated in patients with a variety of chronic pain 
conditions including: CRPS154; chronic prostatitis-chronic pelvic syndrome patients151; and in 
patients with rheumatoid arthritis145,146. In addition, TNF-a inhibitors reduced pain in rheumatoid 
arthritis, supporting the role of this mediator in pain processes330. Furthermore, patients with 
painful neuropathies had elevated TNF-a compared to those with painless neuropathies or 
healthy controls160. Patients with diabetic neuropathy also had increased TNF-a331 and serum 
TNF-a was associated with pain intensity332. Moreover, TNF-a was increased in patients with 
severe sciatica pain (VAS>3) compared to mild sciatica pain (VAS£3) and healthy controls159. 
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Others however have not found an elevation in patients with chronic pain150,153,155,156,165. 
Reasons for these discrepancies are unclear particularly since studies on similar patient 
populations demonstrate conflicting results (ex. CRPS). Methodological differences, such as the 
duration of disease may have contributed. For example, Alexander et al. (2012)154 investigated 
patients with CRPS on average 8.8 years (range .7-36) after disease onset and found increased 
TNF-a while Üçeyler et al. (2007a)155 investigated patients with CRPS on average 12 weeks (range 
1-70) after disease onset and found no significant difference in TNF-a compared to controls. 
Therefore, different stages in disease pathology may have played a role in these discrepant 
findings. In addition, cross-study variability in the inclusion criteria for healthy controls may also 
have contributed to differences. For instance, Lundh et al. (2013)151 found significant differences 
between patients with chronic prostatitis and controls but only after removing participants with 
comorbidities. Other studies did not explicitly exclude participants with health problems that 
could impact immune and inflammatory processes (for example see Slade et al. (2011)153) 
potentially obscuring any effects. Regardless, taken together, the evidence from molecular and 
animal studies and the large number of studies that have a found an association between TNF-a 
and chronic pain support the importance of TNF-a as a potential predictor of risk for post-
operative pain.  
Available research on acute pain and TNF-a in humans is limited. TNF-a in the synovial 
fluid from acutely painful knees secondary to anterior cruciate ligament tears was not 
significantly different than those with non-painful anterior cruciate ligament tears143. In post-
operative pain, TNF-a was positively correlated with resting and walking pain after surgical repair 
of acute hip fracture in older patients (>60 years)163. However, it was not correlated with resting 
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or walking pain before or after knee arthroplasty164. Surgery for hip fracture was related to an 
acute traumatic event163 while knee arthroplasty was performed in patients with osteoarthritis, 
a progressive chronic painful condition258. This difference in study populations may explain the 
conflicting results of these two studies. The only study identified on TNF-a and post-BCS pain 
found an SNP in the gene for TNF-a was associated with mild persistent pain after BCS259. These 
results require replication and at present, the effect of this polymorphism on protein 
concentrations is unclear, making conclusions difficult to draw.  
Despite discrepancies in the literature, given the available evidence of the role of TNF-a 
in pain sensitization, in animal models and some findings in human pain populations, an 
examination of how baseline levels may impact post-operative pain is warranted. Baseline levels 
of this cytokine could result in heightened baseline sensitization or could increase the response 
to surgical injury, resulting in greater sensitization changes during and after surgery. As such, this 
study explored the relevance of this cytokine in predicting pain after BCS surgery.  
Anti-nociceptive  
Interleukin 10 
IL-10 is an 18kDa anti-inflammatory cytokine involved in attenuation of the inflammatory 
response. It is synthesized mainly by monocytes333,334, macrophages334,335, and T helper cells, 
including TH1, TH2 and TH17 cells 184,336,337. It is also produced by other immune cells including: 
Treg cells338, gd T cells339, cytotoxic T cells340, neutrophils341, NK cells, B cells333, mast cells342, 
dendritic cells343 and by microglia in the nervous system344.  
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The receptor for IL-10 consists of 2 subunits: IL-10R1 and IL-10R2, both of which are 
necessary for signalling345. IL-10R1 is expressed predominantly on immune cells including 
macrophages346, monocytes, NK cells, B and T cells182,333, neutrophils347, dendritic cells, and mast 
cells182. This receptor subunit is also expressed on non-immune cells but typically at lower levels 
requiring upregulation to be effective348. Some non-immune cells that express IL-10R1 include 
fibroblasts349 and epidermal cells350,351. Expression has also been observed in DRG neurons352 and 
on glial cells in the central nervous system353. IL-10R2 is expressed on most cells333 and expression 
is not usually significantly impacted by induction signals348.   
Given the extensive receptor expression, IL-10 has a wide range of effects on immune 
cells including influencing immune mediators, antigen presentation and phagocytosis354. Here I 
will focus on the release of immune mediators that mediate inflammation and changes in 
nociception.  
IL-10’s effect appears to be strongest on macrophages and monocytes354. In 
macrophages and monocytes it inhibits release of immune mediators including TNF-a, IL-6355, IL-
1b, IL-8, granulocyte macrophage-colony stimulating factor (GM-CSF) and granulocyte colony 
stimulating factor (GCSF)356; stimulates release of IL-1Ra357; stimulates release of TNF-a soluble 
receptors (TNF-a antagonist) and downregulates surface TNF-a receptors358; inhibits 
cyclooxygenase-2 (COX-2) reducing production of PGE2359; and inhibits the release of reactive 
oxygen intermediates360. It also reduces the recruitment of macrophages361. In neutrophils it has 
similar effects including inhibiting release of TNF-a, IL-1b, IL-8362; increasing release of IL-1Ra363; 
and inhibiting COX-2 protein expression341. All of these changes dampen the inflammatory 
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response and reduce the amount and effectiveness of pro-inflammatory and pro-algesic 
molecules.   
IL-10 acts differently on different classes of T cell. It inhibits the release of IFN-g and IL-2 
from TH1 cells336 and activates Treg cells to reduce TH17 mediated inflammation364. It also 
decreases TH2 differentiation and survival365. In addition, IL-10 reduces IL-8 mediated 
chemotactic responses of T helper cells366. These effects further dampen the inflammatory 
response by decreasing the presence of pro-inflammatory T cell subsets.  
IL-10 also directly affects cells in the nervous system. It decreases IL-1b, TNF-a, IL-6 and 
CCL2 (chemotactic factor for monocytes and basophils) expression by astrocytes367. It also 
increases TGF-b expression by astrocytes, which in turn inhibits microglial activation367. IL-10 
reduces IL-6 expression by microglia367 and induces b-endorphin, an endogenous opioid peptide, 
expression by microglia368. Direct effects on neurons include reducing baseline expression of 
Nav1.6 and Nav1.8 at the mRNA and protein level in DRG neurons352. It also abolishes TNF-a 
induced upregulation of Nav1.3, Nav 1.6 and Nav1.8352. These changes reduce the inflammatory 
mediators present locally in the nervous system and directly reduce the excitability of the 
neurons in the DRG.  
Data from animal models of pain link these molecular changes to behavioural responses, 
further supporting the anti-nociceptive effects of this cytokine. For instance, after partial nerve 
ligation and chronic constriction injury, rats exhibited significant mechanical allodynia and IL-10 
levels were significantly decreased369. Further, blocking IL-10 signaling with intrathecal 
administration of an IL-10 antibody delayed resolution of inflammatory hyperalgesia334 and 
prevented recovery from paclitaxel-induced allodynia370 supporting the role of endogenous IL-10 
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signaling in the resolution of inflammatory and nerve-injury-induced sensitization. In addition, 
intrathecal delivery of IL-10 attenuated allodynia in rat nerve injury models352,368,371 and inhibited 
spontaneous DRG discharges triggered by paclitaxel therapy, reducing allodynia370. These studies 
further support the importance of IL-10 in attenuating sensitization, particularly after nerve 
injury.  
Although IL-10 seems to be important in recovery from nerve injury and preventing 
allodynia associated with nerve injury in animal models, studies on IL-10 in patients with chronic 
pain have reported conflicting results. In support of findings in animal models, IL-10 was 
decreased in patients with chronic pain from post-traumatic neuralgia or distal painful non-
diabetic polyneuropathy156, fibromyalgia147, CRPS155 and chronic widespread pain150 compared 
to healthy controls. Some studies also reported IL-10 was inversely correlated with pain 
intensity147,156,251. In addition, patients with painful neuropathies had decreased IL-10 mRNA 
compared to patients with painless neuropathies160. IL-10 was also decreased in patients with 
severe sciatica pain secondary to lumbar disc herniation compared to those with mild pain159.  
Overall, the above studies support that IL-10 reduces pain, however, some studies did 
not find a significant difference in patients with pain compared to controls154,162,165. Surprisingly, 
a few studies found increased IL-10 in patients with certain chronic pain conditions including in 
patients with chronic prostatitis-chronic pelvic pain syndrome152, in patients with small fiber 
neuropathy161 and in patients with rheumatoid arthritis compared to healthy controls145. These 
increases could reflect protective mechanisms in which increased IL-10 was produced to counter 
the pro-inflammatory and pro-algesic responses, in order to re-establish homeostasis.  
44 
 
The regulatory role of IL-10 makes interpreting these discrepant findings in chronic pain 
conditions difficult. Findings on the acute effects of IL-10 were also mixed. IL-10 in the synovial 
fluid of acute, painful knees secondary to anterior cruciate ligament tear were not significantly 
different from levels in controls143. On the other hand, a study on IL-10 in synovial fluid from 
acute, painful knees secondary to meniscal tear found significantly higher levels in painful knees 
compared to non-painful knees144. Different timelines in these studies (examination within six 
weeks of injury143 vs. within six months of injury144) may have influenced these differences. The 
fact that one study showed increased IL-10 and one showed no difference in the acute pain 
setting makes understanding if and how IL-10 may affect one’s risk for post-operative pain 
unclear and suggests more research is needed.  
The only study identified investigating IL-10 and post-surgical pain found an IL-10 
haplotype that was associated with reduced risk for severe persistent post-surgical pain after BCS 
however, they did not report on the effect of the polymorphism on protein levels197 making these 
findings difficult to interpret.  
While evidence in animals strongly supports the anti-nociceptive effect of IL-10, human 
studies report discrepant findings. Gene vector therapies currently being developed to treat 
neuropathic pain support the anti-nociceptive effect of IL-10. Intrathecal delivery of plasmid IL-
10 gene vector has been shown to successfully reduce allodynia in rats, and animal studies are 
ongoing to develop IL-10 gene therapy treatments to be used for neuropathic pain371. See 
Milligan et al. (2012)372 for a more complete description of the IL-10 gene therapy options being 
explored. Importantly, this supports not only the anti-nociceptive effects of IL-10 but also that IL-
10 is potentially modifiable.  
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Human data on IL-10 and pain is mixed, possibly due to the regulatory function of this 
cytokine. However, the strong evidence from cellular and animal models suggests increased 
research on IL-10 and pain in humans is needed. Understanding IL-10 as a risk factor for post-
operative pain is particularly important as with the development of gene therapies, prophylactic 
treatment to prevent post-surgical pain may be possible372. This study aimed to determine if 
there is an association between baseline IL-10 and post-operative pain.  
Immunoregulatory 
In addition to cytokines that can be classified as primarily pro-inflammatory or anti-
inflammatory, some cytokines have bimodal effects and immunoregulatory effects.  
Interleukin-2 
IL-2 is a 15 kDa protein produced primarily by T helper cells, particularly Th1 cells373–375. 
IL-2 is also produced by other T cells, including cytotoxic T cells376, dendritic cells, NK cells375,377, 
and B cells378.  
The IL-2 receptor has three subunits: IL-2Ra, IL-2Rb and IL-2Rg. IL-2Rb and IL-2Rg form a 
receptor with low affinity for IL-2. The low affinity receptor is expressed at low levels on memory 
T helper cells and high levels on memory cytotoxic T cells375. A trimeric receptor containing all 
three subunits forms the high affinity receptor379. The differential expression of the high affinity 
receptor is believed to contribute to the bimodal effects of IL-2 signalling380. High expression of 
the IL-2Ra subunit, which helps form the high affinity receptor, is associated with Treg cells while 
low expression is associated with T effector cells380, indicating different sensitivities and providing 
a potential explanation for the different responses to low and high concentrations of IL-2 (see 
below). Expression of IL-2Ra on T and B cells and monocytes requires induction by antigen 
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presentation380,381. Functional receptors have also been identified in primary sensory neurons in 
the DRG382, in the spinal cord379, in higher brain structures such as the hippocampus383, and in 
microglia384.  
IL-2 mediates a range of effects in the immune system that contribute to inflammatory 
responses. Firstly, it alters the expression of cytokine receptors on T helper cells, signalling cells 
to differentiate into subsets385. IL-2 plays a particularly important role in the balance between 
Treg cells and TH17 cells. It inhibits TH17 differentiation386, promotes Treg development387 and 
maintenance376, and promotes TH2 responses388. IL-2 also expands and activates cytotoxic T 
cells376 and upregulates the IL-2Ra subunit on cytotoxic T cells381,389, increasing the response to 
IL-2. It also induces the expression of chemokine receptors on T cells (CC-CKR1 and CC-CKR2) 
enabling recruitment388,390and induces proliferation of NK cells171,391. 
Different levels of IL-2 have differential effects on T cells which may contribute to the 
bimodal effects observed in animal and human studies. High doses of IL-2 preferentially activate 
NK cells and T effector cells while low doses selectively activate Treg cells387 and T memory cell 
differentiation380. The balance between the activation of T effector cells (pro-inflammatory) and 
Treg cells (anti-inflammatory) will determine whether the effect will be predominantly 
proinflammatory or anti-inflammatory.  
One important way IL-2 exerts pro-inflammatory effects is by activating a range of 
immune cells to release pro-inflammatory cytokines. It triggers IFN-g and TNF-a release from 
peripheral blood mononuclear cells, including NK cells171, cytotoxic T cells and T helper cells166. It 
also activates monocytes rendering them cytotoxic181, and induces release of IL-6392 and IL-8393 
from monocytes.  
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On the other hand, some anti-nociceptive effects are mediated by direct interaction with 
the nervous system. Peripherally, IL-2 triggers membrane hyperpolarization, reduced calcium 
currents and reduced intracellular calcium concentrations in DRG neurons by activating µ opioid 
receptors394. In the central nervous system, IL-2 exerts its anti-nociceptive effect at least partially 
by activating opioid receptors and also by increasing leu-enkephalin in the paraventricular 
nucleus and locus coeruleus, two regions of the brain involved in pain processing395.  
These bimodal effects make teasing apart the impact of IL-2 on nociception challenging. 
However, the effect of exogenous IL-2 or IL-2 gene therapy has helped to elucidate how this 
cytokine affects nociception. One study demonstrated different responses to different 
intrathecal doses of IL-2 with high intrathecal doses resulting in thermal and mechanical 
hyperalgesia and low doses resulting in thermal anti-nociception396. These differential effects at 
high and low doses could be related to the varied expression of the high affinity receptor on 
different cell types380. More recent research is investigating muteins or antibody complexes that 
specifically target IL-2R signalling on T effectors instead of T regulatory cells, which would 
preferentially inhibit pro-inflammatory signalling. However this research is in its infancy373.  
As a result of the immunoregulatory properties of IL-2, and the differential effects of 
different concentrations and signalling on different cell types, the effect of IL-2 on pain in humans 
is difficult to predict. Studies in human chronic pain populations have presented conflicting 
results. IL-2 was elevated in some chronic pain populations, including in patients with CRPS 
compared to controls154,155, in patients with small fiber neuropathies compared to controls161, 
and in patients with painful neuropathies compared to those with painless neuropathies160. A 
study on chronic neuropathic, nociceptive or mixed pain found no significant difference in the 
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patient group compared to the controls but did report IL-2 was increased in patients with severe 
pain compared to “light” pain162. All of these studies support a pro-nociceptive effect. However, 
others found evidence of an anti-nociceptive effect. IL-2 was decreased in fibromyalgia patients 
compared to controls,147 and in spinal cord injury patients with neuropathic pain an increase in 
IL-2 was associated with a decrease in pain193. The bimodal effects of this cytokine exerted 
through differential expression of high affinity receptors may be involved in these discrepant 
results380. Some studies have also reported no difference between patients and controls 
including in patients with chronic widespread pain150 and in patients with chronic prostatitis-
chronic pelvic pain syndrome compared to controls151,152. The pathophysiology of both of these 
chronic pain syndromes is varied which could make it difficult to find differences between 
patients and controls in these studies.  
In terms of acute injury, results are also varied. In one study of acute, meniscal tear, IL-2 
was increased in the synovial fluid of painful knees compared to non-painful knees144. However, 
IL-2 did not differ between synovial fluid from knees with acute, anterior cruciate ligament tear 
and asymptomatic knees143. The reasons for these discrepancies are unclear however, different 
time frames were used in these two studies (onset within 6 months144 compared to onset within 
6 weeks143), thus the inconsistent findings may reflect a timing specific role for IL-2 in nociception 
and sensitization. The small number of studies on IL-2 and acute pain make drawing conclusions 
about how IL-2 may influence sensitization in the acute setting challenging.  
Few studies have examined IL-2 and surgical responses. One study found IL-2 is increased 
during and after non-neurological surgery, but they did not investigate the correlation with 
reported pain195. No studies were available that investigated the relationship between IL-2 levels 
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and intensity of any type of post-operative pain, including after BCS. However, given the bimodal 
effects of this cytokine on immune and inflammatory responses, further research is warranted 
to better understand how changes in this cytokine may influence pain. The current study was the 
first to investigate the relationship of baseline IL-2 to pain after BCS.   
Transforming Growth Factor- b 
TGF-b is a 13 kDa cytokine that may also have both pro-nociceptive and anti-nociceptive 
effects depending on the context130. Many cells produce TGF-b including Tregs397,398, TH17 
cells397, monocytes399 and macrophages398, B cells398,400, platelets401, endothelial cells402 and 
astrocytes in the nervous system399. Breast tumour cells can also produce TGF-b making this a 
particularly relevant cytokine in the context of the current study population403.  
Receptors are found on monocytes404, B cells400, T cells405, NK cells406, mast cells133, 
neutrophils407 and fibroblasts408. They are also found on cells of the nervous system including 
neurons (both ventral horn motor neurons and DRG sensory neurons) and glial cells246,409 
suggesting direct effects are likely.  
One of the roles TGF-b plays in the immune response to infection or injury involves T 
cells. It inhibits T cell proliferation405,410 and inhibits cytotoxic T cell maturation410. TGF-b also 
inhibits T cell differentiation into TH1410–412 and TH2 cells410,413 and prevents cytokine production 
by TH1 (IFN-g)411 and TH2 (IL-4)413 cells. TGF-b also induces Treg differentiation414, which 
suppresses the inflammatory response. On the other hand, TGF-b induces TH17 
differentiation386,397 when IL-6 is present412. TH17 cells are usually pro-inflammatory, however, 
strong activation of TH17 cells by TGF-b also stimulates production of IL-10 inhibiting the 
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inflammatory properties of TH17 cells412. It is unclear at what level of endogenous TGF-b this 
switch to anti-inflammatory effects on TH17 occurs.  
Effects on monocytes and macrophages also appear to be multimodal. In early stages of 
inflammation TGF-b appears to have pro-inflammatory effects. It increases monocyte chemotaxis 
and induces IL-1 expression from monocytes404. However, TGF-b also inhibits monocyte release 
of TNF-a, reactive oxygen intermediates, reactive nitrogen intermediates179, and IL-1 and IL-2 
induced production of IL-6392. Other pro-inflammatory effects of TGF-b include increased 
chemotaxis of mast cells133, neutrophils407, fibroblasts408 and dendritic cells415. The accumulation 
of all these cell types contributes to an increased inflammatory response. TGF-b also induces 
COX-2 expression resulting in increased PGE2 in muscle cells416. Other anti-inflammatory effects 
include inhibiting IL-2-dependent proliferation and antigen presentation functions of B cells400, 
inhibiting cytolytic functions of NK cells406 and inhibiting IL-6 and IL-8 expression by endothelial 
cells417.  
In the nervous system, both pro-nociceptive and anti-nociceptive effects have also been 
described. TGF-b increases capsaicin-induced calcium influx in primary sensory neurons in the 
DRG418 and results in a less negative resting membrane potential and reduced activation 
threshold of DRG neurons409. The mechanism behind these changes likely involves modulation of 
the expression of voltage-gated potassium channels in DRG neurons and downregulation of 
potassium currents409.  
On the other hand, TGF-b inhibits activation of microglia and astrocytes246,419,420 and 
inhibits microglia proliferation246,420. It also reduces TNF-a production by astrocytes, microglia 
and neurons in the dorsal horn419 and inhibits IL-8268, IL-1, IL-6 and superoxide anion production 
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by microglia420. In addition, TGF-b increases expression and function of µ- and d-opioid 
receptors421 and increases synaptic release of enkephalins421,422 in the spinal cord, reducing 
allodynia421. Furthermore, TGF-b upregulates glutamate transporters in the dorsal horn, 
responsible for clearing glutamate from synaptic clefts reducing excitotoxicity419. Together, this 
results in a reduction of pro-nociceptive mediators and an increase in anti-nociceptive mediators.  
While TGF-b seems to be involved in changes relevant to nociception, the ultimate 
outcome of these pro-nociceptive and anti-nociceptive findings is unclear and may depend on 
the local environment. Effects may also differ in the peripheral nervous system vs the central 
nervous system and in healthy vs chronic inflammatory states409.  
Research on animal models has supported mixed effects of TGF-b. Increased endogenous 
TGF-b signaling in mice resulted in decreased mechanical allodynia422. In addition, increased TGF-
b secreted from transplanted bone marrow stromal cells reduced mechanical allodynia and/or 
heat hyperalgesia and decreased neuroinflammation in the spinal cord and DRG423. Intrathecal 
infusion also prevented hypersensitivity from nerve injury and reversed mechanical allodynia and 
thermal hyperalgesia246.  
The above studies support an anti-nociceptive effect; however, TGF-b may have pro-
nociceptive effects in the periphery and anti-nociceptive effects in the central nervous system424. 
In a rat model of chronic pancreatitis, increased TGF-b was observed in the pancreas, and this 
was associated with peripheral nociceptor sensitization and hyperalgesia424. Infusion of TGF-b 
into the pancreas induced sensitization while intrathecal administration of TGF-b reduced 
hyperalgesia424. Others have refuted this suggestion of different effects in the periphery 
compared to the central nervous system. Lantero et al. (2012)425 found that systemic 
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administration of TGF-b reduced mechanical allodynia in mice, and administration of a systemic 
neutralizing antibody that does not cross the blood brain barrier increased mechanical allodynia, 
suggesting anti-nociceptive effects in both the periphery and the central nervous system425. 
Another study proposed the effects of TGF-b in chronic inflammation may differ when compared 
to healthy states409. They found in a rat model of chronic pancreatitis TGF-b antagonism 
decreased hypersensitivity; however, in healthy rats, antagonism increased hyperalgesia409.  
The above studies in animals indicate the effects of TGF-b on inflammation and 
nociception are complex and not easily categorized as pro-nociceptive or anti-nociceptive. 
Human studies have also reported varied conclusions about the effect of TGF-b on pain 
experiences. TGF-b was increased in migraine patients during headache free periods compared 
to controls426 suggesting it could be involved in risk for migraines. It was also increased in patients 
with small fiber neuropathies compared to controls161. However, it was decreased in patients 
with CRPS155 and was not significantly different between patients with chronic widespread pain 
and healthy controls150. Although the pathophysiology behind each of these conditions is poorly 
understood, these discrepancies could reflect differences in the pathologies of the conditions 
examined. Firstly, in small fiber neuropathy it has been proposed that the diseased fibres have 
increased sensitivity to pro-inflammatory cytokines so the increased TGF-b observed may have 
contributed to an anti-inflammatory compensatory process with IL-10161. CRPS on the other hand 
is believed to occur due to exaggerated post-traumatic neurogenic inflammation155. Therefore, 
the decrease observed in CRPS patients may have reflected ongoing inflammation with 
decreased anti-inflammatory cytokines (including IL-10). In addition, in patients with chronic 
widespread pain the finding that TGF-b was equivalent in patients and controls150 may be due to 
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the heterogenous nature of the patient population. Chronic widespread pain includes multiple 
subgroups and these different groups may have different underlying etiologies150.  
Given that Zhu et al. (2012)409 found different effects of TGF-b in healthy compared to 
chronically ill animals, understanding TGF-b’s effects in the acute setting is important. However, 
most research on acute or post-operative pain has not examined TGF-b concentrations and no 
studies were identified that correlated TGF-b with reported pain after surgery. One study found 
it was significantly increased after orthopaedic trauma, although, they did not report pain 
ratings196. A study of BCS found TGF-b decreased after surgery427. However, TGF-b was elevated 
in patients with breast cancer before surgery, possibly due to secretion from the tumor itself and 
then decreased after the removal of the tumour403. Therefore, the observed decrease may not 
be an effect of tissue damage from surgery but rather could be related to the removal of the TGF-
b secreting tumour. The effect of TGF-b on post-operative pain in the breast cancer setting is 
therefore particularly intriguing. The diverse effects on nociception described in cellular and 
animal studies, and the discrepant findings reported in humans make predicting how TGF-b levels 
before surgery may impact sensitization and inflammatory processes challenging. However, this 
cytokine seems to play a role in inflammation and nociception, and given that breast tumour cells 
can secrete it, it may be particularly relevant in pain responses after BCS. This study was the first 
to investigate the role of pre-operative TGF-b in predicting pain outcomes after BCS.   
 Summary 
As this review has shown, a number of cytokines are important in sensitization and pain. 
While gaps exist, taken together, the balance of the available evidence suggests the pro-
inflammatory cytokines IL-6, IL-8, IL-17, IFN-g, and TNF-a contribute to increasing pain 
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perception, while the anti-inflammatory cytokine IL-10 is involved in decreasing pain perception. 
The evidence regarding IL-2 and TGF-β is mixed but overall supports the involvement of these 
cytokines in pain processes. In this study, we predicted the pro-inflammatory cytokines IL-6, IL-
8, IL-17, IFN-g, and TNF-a would be positively correlated with pain outcomes, while the anti-
inflammatory cytokine IL-10 would be negatively correlated with pain outcomes. The direction 
of the relationship between IL-2 and TGF-β and pain outcomes was difficult to predict a priori 
based on the available literature. Nonetheless, we predicted IL-2 would be positively associated 
with pain outcomes, particularly neuropathic pain, given that several studies on patients with 
neuropathies demonstrated a positive association. We predicted TGF-β would be negatively 
associated with pain outcomes as in two out of three studies in humans, the difference between 
TGF-β in patients and healthy controls paralleled differences found in IL-10, suggesting an anti-
inflammatory role.  
Given the evidence for the changes induced by each of the cytokines described, a greater 
pro-inflammatory cytokine profile may facilitate pain susceptibility428 as was found in PPSP after 
inguinal hernia repair429. Some studies have examined the post-surgical inflammatory response; 
however, baseline levels need to be further explored. Studies examining pre-operative cytokines 
have almost never considered psychological factors simultaneously. This was the first study, to 
our knowledge, to measure baseline levels of IL-2, IL-6, IL-8, IL-10, IL-17, IFN-g, TGF-β and TNF-a, 
and other biopsychosocial variables simultaneously to identify risk factors for APSP.  
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2.5 Risk Factors for Post-Surgical Pain 
The biopsychosocial model of pain was developed from the Gate Control Theory and is 
compatible with the Neuromatrix Model of Pain. It conceptualizes pain as a dynamic, 
bidirectional interaction between a range of biological, psychological and social factors16. 
Importantly, these contributing factors all influence one another, suggesting various complex 
interactions rather than unidirectional effects. According to this framework, post-surgical pain is 
likely to be predicted by a range of biopsychosocial factors.  
Surgical factors  
Surgical procedure is associated with APSP, partly due to differences in extent of tissue 
damage. Tissue damage and potential nerve damage lead to inflammation and sensitization 
which increases pain98. Patients undergoing breast reconstruction are at greater risk than those 
undergoing mastectomy without reconstruction3 and patients having mastectomy are at greater 
risk for post-operative pain than those undergoing lumpectomy430–432. Breast reconstruction 
increases the risk of damage to nerves including the lateral pectoral, thoracodorsal and long 
thoracic nerves433. ALND, which is more invasive, increases risk of post-operative pain compared 
to SLNB432,434,435. Importantly, ALND increases risk of damage to the intercostobrachial nerve 
(ICBN), which innervates the skin of the axilla and the medial, proximal arm, and could lead to 
NeP6. Nonetheless, surgical procedure cannot fully explain the variance in APSP, necessitating 
consideration of other factors.  
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Demographic Factors  
Age. The relationship between age and APSP is unclear with reports of no relationship436–
438 and decreases3,7,430,432,434,435,439–443 with age. Mechanisms for any potential relationships are 
unclear444 but may include changes in life stage and psychosocial factors445 as well as changes in 
the immune system446. Younger women may show greater levels of distress compared to older 
women prior to surgery which could contribute to their post-operative pain6,434.  
Correlations between aging and cytokine levels have been extensively studied; however, 
conclusions vary due to differences in subject selection and assay method. IL-6 elevations with 
age are the most consistently reported446–448 although some have found no significant 
difference449. Increased TNF-a has been reported446,447 but not by all449,450; and increased IL-10 
446,447 with age has also been reported but not by all448,449. Baseline IL-8 is increased in older 
adults446 in some studies but not all449. Greater increases in IL-6 and IL-8 in older than younger 
surgical patients suggest a more robust immune response with age that could influence pain256. 
While the relationship between age and APSP as well as the mechanism behind any relationship 
is unclear, the influence of age on APSP was examined in this study.  
Biological and Health Status Factors  
Elevated body mass index (BMI) has been linked to chronic inflammation451 and may 
contribute to post-surgical pain by sensitizing the nervous system pre-operatively. Motaghedi et 
al. (2014)452 found obesity was related to the severity of the post-surgical inflammatory response 
however they did not measure the association with pain. Some have proposed that obesity 
affects handling of the ICBN, and thereby, post-surgical NeP453. Although several studies have 
found no correlation between BMI and post-BCS pain3,432, others have found increasing BMI was 
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associated with greater opioid consumption, even after correcting for weight435. Some studies of 
PPSP after BCS have reported positive associations with BMI3,454,455 however, others have 
not456,457. In general surgery populations, results have also varied with reports of positive 
correlations253,458,459 and no associations429,437,442,443,452. One study found BMI predicted APSP 
quality in younger but not older surgery patients460. Importantly, BMI may be positively 
correlated to movement-related pain but not pain-at-rest one year post-BCS461 suggesting the 
outcome measure may contribute to the discrepancies. Other methodological differences, 
especially in pain measurement, may have also contributed to discrepancies457,462. Many APSP 
studies have not considered BMI, and a systematic review found only 2/48 studies included BMI 
as a possible predictor441. Given the inflammatory status associated with elevated BMI, 
clarification of how BMI, inflammatory cytokine levels, and psychological factors influence APSP 
is needed.  
Psychological Factors 
When nociceptive signals arrive at the brain, various regions are involved in formulating 
the perception of pain through a complex network of interacting pathways19. Crucially, many of 
these supraspinal structures are also involved in emotional and cognitive functions67. Emotional 
and cognitive factors may influence pain pathways in a number of ways: by contributing to 
changes in inflammatory cytokines; by activating descending modulation pathways, therefore 
affecting spinal processing; or by affecting cerebral processing. Various psychological factors 
have been consistently associated with post-surgical pain outcomes.  
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Anxiety. 75% of patients awaiting BCS experience anxiety463, the most consistently 
reported psychological risk factor for severe APSP after BCS430,431,435,464. Anxiety was positively 
correlated with pain after other surgeries as well7,437,441–443,465–467. The association between pain 
and anxiety is well established468 and dysregulation of cytokines implicated in pain processes 
have been observed in patients with anxiety. Liu et al. (2012)146 found increased IL-17 in patients 
with rheumatoid arthritis and anxiety compared to those without anxiety. Others have reported 
increased IL-6 in anxious participants469. This group postulated that the increased threat 
perception associated with anxiety may lead to more frequent and amplified activation of the 
stress response469. Others however, did not find this association470. In patients with colorectal 
cancer, serum IL-6, IL-8 and TNF-a were found to be positively correlated with anxiety, and serum 
IL-10 was negatively correlated with anxiety471. This suggests the association between 
psychological factors and pain could be partially mediated through changes in inflammatory 
cytokines. 
In addition, anxiety is related to dysfunction in the ACC and the prefrontal cortex, 
resulting in reduced top-down control of emotional regulation tasks, particularly in the 
amygdala472. Long term potentiation and changes in the ACC and prefrontal cortex in chronic 
anxiety conditions may result in neuronal activity that impacts normal sensory processing, 
resulting in increased sensitivity and activity in pain-related brain areas468. Activation in the 
prefrontal cortex, and ACC is observed with anxiety and with pain473,474. Increased activity in the 
entorhinal cortex (part of the hippocampus), an area important for memory consolidation, prior 
to pain predicted activity in areas of the brain associated with affective (perigenual cingulate) 
and intensity (mid-insula) processing66. Fairhurst et al. (2007)56 also reported anticipation prior 
59 
 
to a noxious stimulus was correlated with increased activity in the entorhinal cortex in addition 
to the PAG and VTA and the activity in these regions predicted pain-related activation in the 
posterior insula. The more anticipatory anxiety the patient reported prior to the stimulus, the 
greater activation of the PAG and reported pain intensity during the stimulus56. Individuals 
demonstrating increased trait anxiety had greater activity in the anterior insula and the amygdala 
in response to an emotional processing task475 and lorazepam, an anxiolytic drug, reduced 
activity in these brain regions, further supporting their involvement in anxiety476. The amygdala, 
a component of the limbic system associated with the emotional-affective dimension of pain477, 
is particularly important for fear and anxiety processes468, and may be involved in fear associated 
with pain71,477. The activation and dysfunction of multiple brain areas that are implicated in pain 
processes during anxiety supports the relationship between anxiety and pain. The relationship 
between anxiety and pain is bidirectional474, and this study considered anxiety as a pre-operative 
predictor of post-surgical pain outcomes.  
Depression has also been associated with increased APSP after BCS431,464 and other 
surgeries439,442,465–467. The bidirectional relationship between depression and chronic pain is well 
established, with individuals who are pain-free and depressed at increased risk of developing 
chronic pain, and patients with chronic pain at increased risk of developing depression474.  
In 1991, Smith proposed the macrophage theory of depression which suggests excessive 
secretion of inflammatory cytokines, including TNF-a, is the underlying cause of depression478. 
Since, multiple studies have implicated a number of pro-inflammatory cytokines in depression, 
particularly IL-6 and TNF-a479. Depression has been positively correlated with IL-6470,479–483 and a 
greater IL-6 response to experimental stressors has been found in depressed than non-depressed 
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patients481,484, suggesting patients with depression may not only have pre-sensitized immune 
systems but may have greater post-surgical IL-6 increases. Cells from individuals with depressive 
symptoms have also shown increased production of IL-8 in response to inflammatory stimuli485, 
so depression could predispose individuals to a greater inflammatory response after surgery, and 
therefore increased APSP. Increased TNF-a has also been found in depressed patients69 but not 
consistently480,486. Another study found the magnitude of depressive symptoms in women after 
BCS correlated with TNF-a482. In colorectal cancer patients, serum IL-6, IL-8 and TNF-a were 
found to be positively correlated with depression and serum IL-10 was negatively correlated with 
depression471. Therefore, both the increased resting levels of inflammatory cytokines in patients 
with depression as well as increased inflammatory reactivity to stress480 could increase the risk 
of APSP in depressed patients. (For an in depth review of the effects of cytokines on depression 
see Felger & Lotrich (2013)480 or Slavich & Irwin (2009)487).  
Dysfunction in the serotonin488 and norepinephrine489 neurotransmitter systems are also 
implicated in the proposed pathophysiological mechanism of depression490 and these systems 
are involved in descending pain pathways491. A number of functional imaging studies have found 
depressed mood to be associated with changes in activity in brain regions associated with 
processing of nociceptive stimuli, particularly areas implicated in affective processing492. 
Giesecke et al. (2005)492 compared cortical responses to painful pressure stimuli in the brains of 
patients with major depressive disorder compared to healthy controls and found no difference 
in activity in somatosensory cortices (sensory-discriminative dimension of pain) but found 
increased activity in the anterior insula and in the amygdala in patients with major depression. 
Increased activity in response to painful stimulation has also been reported in the thalamus, the 
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prefrontal cortex57 and the amygdala493 in patients with depression. Decreased activity in the 
ACC and PAG, regions involved in descending modulatory pathways, has also been observed in 
depressed patients exposed to painful stimuli493. Further evidence from fMRI studies suggests 
depressed patients may experience increased levels of affective processing before experiencing 
pain57, demonstrated by increased activity in the amygdala, anterior insula and ACC493. 
Depression has also been linked to a reduction in inhibitory descending modulation491 and 
malfunctioning in the ACC477. Taken together, depression could predispose patients to APSP by 
altering inflammatory cytokine levels or reactivity, or by supraspinal mechanisms in areas of the 
brain associated with both depression and pain.  
Pain catastrophizing is an amplified negative response to actual or expected painful 
experiences494. It has been positively correlated with pain after BCS430,434 and other 
surgeries438,441,465,495,496. It is one of the most important factors predicting pain intensity and 
disability and is associated with poorer pain treatment outcomes497,498. 
The association between inflammatory cytokines and pain catastrophizing has been less 
extensively studied however, pain catastrophizing was associated with greater pain-related 
increases in IL-6 in an experimental pain study499 suggesting alterations in cytokines could play a 
role in the effect of pain catastrophizing on pain outcomes.  
Pain catastrophizing is also believed to mediate increased pain via increased attention to 
stimulation and increased emotional responses491. In response to painful mechanical stimuli, high 
catastrophizers demonstrated increased activity in the medial frontal cortex and cerebellum 
(anticipation of pain), the dorsal ACC and prefrontal cortex (attention to pain) and the claustrum 
(closely linked to the amygdala; emotional processing of pain)500. According to an fMRI study, 
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during mild pain, activity in brain regions, including the ACC and the insula, were positively 
correlated to PCS scores, suggesting increased emotional processing501. During moderate pain, 
PCS scores were negatively correlated with activity in brain regions associated with top-down 
control, including the dorsolateral frontal cortex, which may suggest impaired descending 
control501.  
Pain expectations. Higher pain expectations have been associated with increased post-
BCS pain intensity432. No studies were identified that examined the association between cytokine 
levels and pain expectations.  
However, in brain imaging studies the anterior insula, ACC, thalamus and PAG are all 
activated during anticipation of pain56. In a study on healthy volunteers, expectations of reduced 
pain were associated with a reduction in the pain intensity reported after painful heat stimulation 
as well as a reduction in activity in brain areas associated with pain processing, including the 
thalamus, primary and secondary somatosensory cortices, insula, ACC, prefrontal cortex and 
cerebellum502. Based on nocebo experiments, negative expectations are mediated by 
hyperactivity of the hypothalamic-pituitary-adrenal axis, increased CCK, and decreased 
dopamine and opioid activity in the nucleus accumbens503. Activity in the PAG, a region important 
in descending pathways, is also associated with anticipation of pain and perceived pain 
intensity477. Increased anticipation of pain is associated with increased activity in the anterior 
insula, and the amount of activity correlates with ratings of pain intensity477. 
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Pain and Treatment History Factors  
Pre-operative pain has been reported as a risk factor for APSP in general 
surgical7,437,439,441–443,465,466,496 and BCS populations435,436. Pre-operative pain could contribute to 
pre-operative nervous system sensitization due to alterations in pro and anti-inflammatory 
cytokines504. In addition, nerve or tissue damage by tumour growth could contribute to pre-
operative pain and neuroplastic changes prior to surgery504. Pre-operative pain could also 
influence pain beliefs and expectations, and therefore, modulation in the spinal cord and brain, 
leading to more severe APSP7. Patients with pre-operative pain, particularly chronic pain, may 
also be predisposed to post-surgical pain due to shared genetic and psychosocial risk factors455.  
Previous breast surgery may also increase the risk of post-surgical pain due to changes 
in the patient’s expectations and response shifts as a result of previous experience505. 
Neurobiological changes in the surgical area may also occur after previous surgery predisposing 
these patients to pain506. Previous surgical experience has been reported as a risk factor in a 
general surgical population460.   
Hormonal therapy is associated with musculoskeletal pain507 and has been associated 
with increased risk of PPSP after BCS454. Researchers have suggested the association between 
hormonal therapy such as aromatase inhibitors with joint pain is related to reduced estrogen 
levels508. In one study, increased IL-4 and reduced IFN-g were correlated with reduced pain 
intensity from aromatase inhibitors suggesting inflammatory mediators may contribute to the 
mechanism of aromatase inhibitor related pain508.  
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Previous radiation or chemotherapy could also increase the risk of post-operative pain 
due to neurobiological changes. Studies have reported post-operative radiation or chemotherapy 
was associated with increased PPSP456,509,510. Both radiation and chemotherapy treatment, 
particularly regimens with taxanes, platinum agents or vinca alkaloids, are associated with 
neuropathic pain511. Chemotherapy induces axonal injury which activates an inflammatory 
response that is, in part, mediated by cytokines512. Different mechanisms of neurotoxicity have 
been reported for different types of chemotherapy, however all involve upregulation of gene 
expression associated with inflammatory and immune responses, including inflammatory 
cytokines512. In addition, radiation induces fibrotic changes, which are associated with increased 
IL-6 and TGF-b, and decreased IL-10513. These cytokine changes could affect excitability of 
neurons in the breast and axilla area.    
Many patients receive chemotherapy, radiation or hormonal therapy after surgery. As a 
result, only one study was identified that investigated pre-operative chemotherapy and radiation 
and they did not find an association with APSP3. Since some women may have had a previous 
cancer that was treated with chemotherapy, radiation or hormonal therapy and some women 
receive neo-adjuvant chemotherapy in order to shrink the tumour to facilitate surgery, this may 
be an important variable to assess pre-operatively. Therefore, these variables were considered 
in the current study because of their association with both PPSP and non-surgical pain. 
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2.6 Pain Outcomes 
Pain intensity, or how much it hurts514, was considered both at rest and with movement. 
Different correlates have been reported for resting pain and movement-evoked pain in both 
APSP442,515 and PPSP461. For example, signs of neuropathic pain 1 week after BCS, contributed to 
the model predicting pain at rest one year after surgery, but was not included in the model 
predicting movement-related pain461. BMI was included in the model for movement-related pain 
but was not included in the model for pain at rest461. Movement-evoked pain is also a proxy for 
mechanical hyperalgesia8 and provides information on the impact of pain on physical 
functioning516. Opioid medications may be less effective at reducing movement-evoked pain than 
resting pain4,517 so understanding risk factors for each could help tailor analgesia plans. Despite 
these differences, a systematic review found 39% of post-operative pain studies did not include 
movement-evoked pain as an outcome, and 52% did not specify whether they were measuring 
resting pain or movement-related pain516. The current study measured both resting and 
movement-related pain intensity to better elucidate differences in factors contributing to APSP. 
Pain quality, or how the pain feels518, was also assessed in this study. APSP is often 
described as aching, tender, throbbing, sharp and tiring-exhausting519. Changes in pain quality 
have been reported to impact interference beyond changes in intensity, supporting the 
importance of assessing both intensity and quality520. Evaluating pain qualities may provide 
information about the etiology of pain which could lead to more effective treatment521. For 
instance, Minocycline had no impact on overall pain intensity but reduced scores on the affective 
scale of the Short Form-McGill Pain Questionnaire, a measure of sensory and affective pain 
qualities522. IL-6 and depression symptoms explained 21% of the variability in pain quality in 
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patients with back pain253 so understanding the impact of cytokines and psychosocial factors on 
pain qualities may further our understanding of those at risk for particular types of pain.  
NeP was also investigated in the present study. Nociceptive pain and NeP may respond 
to different pharmacological interventions so determining risk factors for each is essential523. 
Given the importance of pain qualities, this study developed biopsychosocial models predicting 
pain intensity at rest and with movement, pain qualities and NeP separately. 
 
2.7 Consequences of Unrelieved Post-Surgical Pain 
The amplified sympathetic activity associated with severe APSP increases the risk of 
complications in the cardiovascular, gastrointestinal, immune, muscular, pulmonary and renal 
systems4,524. APSP also impacts psychological functioning and leads to reduced patient 
satisfaction, delayed discharge from hospital and post-anesthesia recovery units and 
unanticipated readmissions4. In older people, it can increase the risk of post-operative delirium 
and cognitive dysfunction4. Severe APSP is also a predictor for PPSP, which occurs in 22-70% of 
patients3,455. Improved management of APSP is essential to reduce the likelihood of these 
complications. 
 
2.8 Relevance and Importance 
Despite advances in surgical technique and our understanding of pain, post-operative 
pain control remains inadequate. Identifying high-risk patients prior to surgery will allow pre-
operative and post-operative care to be adjusted based on risk. Modifiable factors identified in 
the pre-operative period will also provide a basis for research on targeted pre-operative 
interventions. While multiple studies have examined psychological, surgical and demographic 
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variables as risk factors for APSP, this is the first study, to our knowledge, that considered these 
factors simultaneously with baseline inflammatory cytokine levels to develop models predicting 
pain at rest, pain with movement, pain qualities and NeP after BCS.  
 
2.9 Objectives 
To develop biopsychosocial models of pre-operative risk factors to predict pain intensity 
at rest; pain intensity with movement; sensory and affective pain qualities; and neuropathic pain.  
 
2.10 Hypotheses 
1. At 24 hours after surgery, each pain outcome (NRS-R, NRS-M, SF-MPQ and SF-NPQ), will 
be predicted by a range of preoperative biopsychosocial factors. We predict that 
psychological factors will most strongly predict the outcomes, although surgical factors 
and inflammatory cytokine concentrations at baseline will also contribute significantly to 
each model.  
2. There will be overlap between each of the models developed, however, we expect there 
to be differences in the variables that contribute to each model.  
3. IFN-g, IL-2, IL-6, IL-8, IL-17, TNF-a will be associated with increased pain, while IL-10 and 
TGF-b will be predictive of decreased pain.  
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3 METHODS 
This study was part of a larger, ongoing longitudinal study of post-operative pain after 
BCS (Canadian Cancer Society Research Institute Grant no. 18367). Ethics approval was obtained 
from the University Health Network (UHN) and York University. 
Sample, Inclusion and Exclusion Criteria. 300 women scheduled for unilateral or 
bilateral mastectomy at UHN were recruited to the larger study. The 86 women who consented 
to a pre-operative blood draw and who completed a post-operative follow-up were included in 
this analysis. Inclusion criteria: ³18 years old, able to read and write English sufficiently to provide 
informed consent and complete questionnaires, Class 1-3 on the American Society of 
Anesthesiologists Physical Status Classification System525. Patients with a variety of breast cancer 
diagnoses (including ductal carcinoma in situ, invasive ductal carcinoma and invasive lobular 
carcinoma), stage 0-4, and those undergoing prophylactic surgery were recruited. Exclusion 
criteria: significant central nervous system, respiratory, cardiac, hepatic, renal or endocrine 
dysfunction and/or any significant associated sequelae; cognitive impairment or documented 
diagnosis of a DSM-IV Axis 1 disorder; contraindication to opioids or acetaminophen; 
documented substance abuse or dependence within one year; pregnant or breastfeeding within 
six months; use of exogenous hormones within three months; immunization within 30 days; 
blood donation within 60 days; acute or infectious illness, allergic reactions, herbal supplements, 
physical injuries or dental work within two weeks.  
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Procedure. Preadmission. Patients were recruited from the survivorship class at Princess 
Margaret Cancer Centre and the preadmission clinic at Toronto General Hospital. All patients 
approached were documented, and the reason for exclusions recorded. Informed consent was 
obtained, and the Short Orientation-Memory-Concentration Test was administered. No patients 
had scores suggesting cognitive impairment. Patients completed a comprehensive package 
including demographic information, menopausal status, pain expectations, history of chronic and 
ongoing pain problems, history of breast surgery and a measure of pre-operative pain at rest. A 
research assistant (RA) certified in phlebotomy requested permission to obtain a blood sample 
or to add additional vials to blood work ordered by physicians. Two lavender EDTA-coated 
Vacutainer® blood collection tubes were filled, allowing for a backup sample. Immediately after 
blood was drawn, it was centrifuged and plasma was separated and frozen at -80˚C until analysis. 
Patients were given a take-home package including measures of anxiety, pain catastrophizing, 
and depression, which they completed and returned on the day of surgery. The RA also 
completed a chart review for disease and health information (Charlson Comorbidity Index, 
Karnofsky Performance Status, diagnosis, stage and history of cancer related treatment). BMI 
was calculated based on patient’s height and weight as measured at the preadmission 
assessment (BMI=weight (kg)/height2 (m)).  
Intraoperative Management. Intraoperative management followed standard practice 
and may have differed slightly between patients. Decisions regarding intraoperative anesthesia 
and analgesia were made at the discretion of the anesthesiologist.  
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Post-Operative Follow-up. Post-operative management followed standard practice. 
Decisions regarding management were made by the patient’s care team and therefore may have 
differed slightly between patients. Typically, patients received IV morphine 2-4mg and 650-
1000mg of acetaminophen every six hours as needed. On the first post-surgical day, an RA visited 
or called the patient if they had been discharged. The Confusion Assessment Method was 
completed to assess delirium. There were no cases of scores suggesting delirium that required 
nursing intervention. Measures of pain at rest, pain with movement, pain qualities, and NeP were 
completed. When a patient could not be reached, pain ratings were abstracted from the patient’s 
chart. Only pain at rest and occasionally movement-evoked pain were available from patient 
charts. Surgical information (type and length, complications, intraoperative and post-operative 
medications) and adverse events were recorded. See Appendix 2 for a summary of measures 
collected for the larger, longitudinal study.  
 
3.1 Measures 
Measures of Cognitive Status. The Short Orientation-Memory-Concentration Test 
assessed cognitive impairment pre-operatively. Scores can range from 0 to 28 with <18 indicating 
cognitive impairment. It has been used in cancer patients526. The Confusion Assessment Method 
was used to assess for post-surgical delirium. It is valid and reliable527.  
 Measures of Pain. Numeric rating scale at rest (NRS-R) and with movement (NRS-M). 
Patients selected a number from 0 (no pain), to 10 (worst possible pain). The NRS-R measured 
pain at rest. For movement-evoked pain, patients completed NRS-Ms after taking two maximal 
inspirations. NRSs are valid for post-surgical pain528. The Short-Form McGill Pain Questionnaire 
(SF-MPQ) was used as a multidimensional rating of the intensity of 11 sensory and 4 affective 
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pain qualities as none, mild, moderate and severe. It is valid and reliable in the assessment of 
cancer pain529 and post-surgical pain518,519. Total scores can range from 0-45 with higher scores 
indicating increased total affective and sensory pain intensity. The Short-Form Neuropathic Pain 
Questionnaire (SF-NPQ) is a valid and reliable measure of intensity of NeP qualities530. Patients 
reported the intensity of tingling, numbness and pain due to touch from 0-100530. Total scores 
can range from 0-300, with higher scores indicating increased intensity of neuropathic pain 
qualities. Answers were scored in two ways: firstly, the sum of responses to the three questions 
was used for the model outcome as this study was primarily interested in the presence of any 
neuropathic pain qualities; secondly, a validated scoring system530 which aims to categorize 
patients as experiencing neuropathic vs. non-neuropathic pain was used to better characterize 
the population of patients with probable neuropathic pain. Pain expectations were assessed by 
asking patients to answer three questions on a scale of 0 to 10: how intense do you expect the 
pain to be immediately following your surgery when you first wake up?; How intense do you 
expect the pain to be after you are given the pain medication?; How intense do you expect the 
pain to be one week following your surgery? The average of the answers to the three questions 
was used.  
Measures of Health Status. Charlson Comorbidity Index (CCI) is a weighted index of 19 
comorbid conditions that was used to obtain a total comorbidity score. Higher scores indicate 
more comorbidity. It is valid and reliable in breast cancer and surgical patients531. Karnofsky 
Performance Status (KPS) was used as a measure of functional status (0= ”dead” to 100= ”no 
evidence of disease”). It is valid and reliable in cancer patients532.  
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Measures of Psychosocial Status. The Centre for Epidemiologic Studies – Depression 
Scale (CES-D) was used to measure depression. It is a 20-item measure that is valid and reliable 
in breast cancer patients533. Total scores range from 0-60 with higher scores indicating more 
depressive symptoms. The Pain Catastrophizing Scale (PCS) is a 13-item questionnaire that was 
used to measure pain rumination and magnification and helplessness in managing pain. Scores 
range from 0-52 with higher scores indicating increased pain catastrophizing. It is valid and 
reliable in adult pain populations534. The State-Trait Anxiety Inventory measured state anxiety 
(STAI-S), anxiety in response to specific situations, and trait anxiety (STAI-T), a general tendency 
towards anxious feelings, each with 20 items. Possible scores on each scale range from 20-80 
with higher scores indicating increased anxiety. It is valid in surgical and cancer patients535.  
Plasma Cytokine Levels. The Meso Scale Discovery (MSD) V-PLEX Cytokine Panel 1 
(human) kit measured plasma IL-17. Plasma TGF-β1 was measured using the MSD 96-Well Multi-
Array® Human TGF-β1 Assay. Plasma IFN-γ, IL-2, IL-6, IL-8, IL-10 and TNF-α were measured using 
the MSD V-PLEX Proinflammatory Panel 1 (human) kit. The manufacturer’s instructions were 
followed (MSD, Rockville, MD, USA). These enzyme-linked immunosorbent assays are validated. 
Plates came pre-coated with primary antibodies and calibrators, diluents, secondary antibodies 
and read buffer solutions were provided. Briefly, multi-analyte lyophilized calibrators were 
diluted to create seven solutions that were included on each plate. Plasma samples were thawed 
on ice. Two-fold dilutions of each sample were made. Each sample was tested twice and the 
mean was used. Samples were incubated for two hours in separate wells on each plate allowing 
cytokines to bind to primary antibodies on the well surface. After washing, detection antibodies 
conjugated with electrochemiluminescent labels were added to each well and incubated for two 
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hours. The secondary antibodies then bound to the bound analytes. Next the plates were washed 
and a read buffer, which creates the environmental conditions necessary for 
electrochemiluminescence, was added. The plates were read using an MSD SECTOR® Imager 
which applied a voltage to the plates causing the bound secondary antibodies to emit light. The 
MSD SECTOR® Imager measured the intensity of emitted light to quantify the analytes in the 
sample. Intensity of light from calibrators allowed for the development of a standard curve from 
which concentrations could be calculated. The use of this curve allowed samples below the 
detection limit but within the curve to be extrapolated. The lower limits of detection (LLODs) 
were: IFN-γ: 0.02pg/ml, IL-2: 0.09pg/ml, IL-6: 0.06pg/ml, IL-8: 0.04pg/ml, IL-10: 0.03pg/ml, IL-17: 
0.74 pg/ml, TGF-β1: 17pg/ml and TNF-α: 0.04pg/ml. Interleukin-1b (IL-1b), Interleukin-4 (IL-4), 
Granulocyte-macrophage colony stimulating factor (GM-CSF) were also explored however, most 
samples were below the detection limit and are therefore not presented.  
 
3.2 Data Analyses 
Missing Data. All data were double checked for data entry errors prior to analysis. 
Missing data was assessed using Little’s Missing Completely at Random test536 and was found to 
be missing completely at random. The mean item response for a particular participant was 
imputed for questionnaires with less than 20% items missing537. When participants were missing 
more than 20% of items on questionnaires used as predictors, total questionnaire scores were 
imputed using maximum likelihood estimates538. No data were imputed for any pain outcome 
(NRS-R, NRS-M, SF-MPQ, SF-NPQ) missing >20% of items. These patients were excluded from the 
model for which their score was missing.  
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Cytokine values below the curve fit were imputed with zero. Analyses were conducted 
with pairwise deletion and with imputed data. No significant differences were found so data are 
presented with imputed data. The intra-assay coefficient of variation (%CV), a measure of 
precision between duplicate samples was examined. A %CV<25 was considered acceptable539. 
There were some samples above this limit: one sample for IFN-g, one for IL-2, three for IL-6, three 
for IL-8, one for IL-10, one for IL-17, and three for TNF-a. These were excluded from subsequent 
analyses using pairwise deletion.  
Descriptive Statistics. Means and standard deviations were calculated for normally 
distributed continuous variables, medians and interquartile range for non-normally distributed 
continuous variables, and frequencies for categorical variables. Data were examined for 
skewness and kurtosis. Z-scores for skewness and kurtosis were calculated by dividing by the 
corresponding standard error. A cut-off of 3.29 was used to determine normality540. Scores on 
the SF-MPQ were not normally distributed (z-score skewness= 6.46, z-score kurtosis = 6.77); 
therefore, a square root transformation was applied as the data were positively skewed and 
contained zero values541. After square root transformation, the z-score of skewness was 1.00 and 
the z-score of kurtosis was 0.69. Age-related differences in descriptive characteristics were 
assessed using Pearson’s correlations for normally distributed continuous variables, Spearman’s 
correlations for non-normal continuous and ordinal variables, and independent t-tests or one-
way analysis of variance tests for categorical variables541.  
The proportion of patients selecting each pain quality on the SF-MPQ Sensory and 
Affective subscales and the SF-NPQ scale was determined. The average number of words chosen 
on each was also calculated. The SF-NPQ was also scored to distinguish between neuropathic and 
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non-neuropathic pain. Independent samples t-tests, Mann Whitney U-tests of medians and 
Fisher’s Exact tests were used to identify group differences.  
Bivariate Analyses. Models to identify pre-operative predictors of acute post-surgical 
NRS-R, NRS-M, SF-MPQ Total, and SF-NPQ were developed. Potential predictors included 
demographic (age), biological and health status variables (pre-operative plasma cytokine 
concentrations, BMI, menopausal status); psychological variables (anxiety, depression, pain 
catastrophizing and pain expectations); surgical variables (surgical procedure, time in hours from 
surgery to follow-up, surgical indication); pain and treatment history variables (pre-operative 
pain (NRS-R pre-op), chronic pain or analgesic use in previous 6 months, ongoing pain problem, 
core biopsy prior to surgery, previous radiation or chemotherapy, previous hormonal therapy). 
Independent t-tests assessed differences in age and pain outcomes for any categorical variable 
with small cell size (<15% of total sample). When no significant differences were found (p>.05), 
these variables were not included as potential predictors. Associations between continuous 
predictors and outcomes were assessed with Pearson’s correlations for normally distributed data 
and Spearman’s correlations for non-normal and ordinal variables541. Associations between 
outcomes and categorical predictors were assessed using independent t-tests. Levene’s test for 
Equality of Variances was used to determine if the assumption of homogeneity of variances was 
met. When Levene’s test was significant at p<.05, Welch’s t-test was used to compare group 
differences on outcomes541.  
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Model Building. Predictor variables that were correlated with any of the outcomes at a 
significance level of p<0.1 were considered for inclusion in all of the multiple regressions. In cases 
where predictor variables were highly correlated (r>0.7), the variable with the least missing data 
or greater literature to support its importance was included538. Backward multivariate 
regressions determined significant pre-operative predictors of acute post-surgical pain 
outcomes. Criteria for removal was p>0.15.  
Assumptions of multiple regressions were investigated. Durbin-Watson’s test was used 
to test for independence of residuals for each model. Partial regression plots of each independent 
variable with each dependent variable were visually analyzed to confirm the presence of a linear 
relationship. Standardized residuals were assessed for normality using the standard error of skew 
and kurtosis. Standardized residuals >±3.3 were considered to indicate an outlier538. Leverage 
values were also examined to identify cases that may be influencing the model. The average 
leverage ((k+1)/n) times 3 was used as a cut off541. Cook’s values were also analyzed as a second 
technique to identify influential points. A cut-off of 1 was used542. Variance inflation factor (VIF) 
values were examined to confirm there was no multicollinearity. All data were analyzed using 
SPSS Version 24.0 for Windows (SPSS. Inc., Chicago, IL). 
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4 RESULTS 
Of the 300 patients included in the larger study, 105 consented to a blood draw. 19 of 
these patients did not complete any portion of the post-operative follow-up and were therefore 
excluded from this analysis. A flow diagram of recruited patients is presented in Figure 1. A total 
of 86 patients had scores on the NRS-R, 83 had scores on the NRS-M, 78 had scores on the SF-
MPQ and 73 had scores on the SF-NPQ. Most missing data involved pre-operative questionnaires 
measuring anxiety, depression, pain catastrophizing and pain expectations. The largest amount 
of missing data was on the STAI-T with 15% of patients missing the entire scale and two patients 
missing one or two items.  
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300 PATIENTS RECRUITED 
105 CONSENTED TO BLOOD DRAW 
 
86 COMPLETED AT LEAST 
SOME OF THE POST-OP 
FOLLOW-UP 
195 REFUSED BLOOD 
DRAW 
3 WITHDREW 
5 EXCLUDED 
Surgery cancelled 
or changed 
location/date 
11 UNREACHABLE 
666 APPROACHED 
366 DECLINED TO 
PARTICIPATE 
Figure 1. CONSORT diagram of participants.  
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4.1 Participant characteristics 
61 patients were recruited from Toronto General Hospital and 25 patients were recruited 
from Princess Margaret Cancer Centre. Demographic information is presented in Table 2. Age 
ranged from 24-81 years. The sample was predominantly white (84.9%) and spoke English as their 
primary language (84.9%). 40 (46.6%) patients underwent prophylactic surgery, 27 (31.4%) had 
non-recurrent breast cancer, 16 (18.6%) had a recurrence to the same breast, 2 (2.3%) had 
residual disease from a previous surgery, and 1 (1.2%) had a recurrence to the opposite breast. 
The majority (84.9%) did not have pain prior to surgery, with only 13 people (15.1%) indicating 
NRS-R pre-op >0.  
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Table 2.  Participant Baseline Characteristics 
 Mean ± SD or Frequency (%) 
Age 50.62 ± 10.96 
BMI 27.39 ± 4.569 
CCI>0 68 (79.1) 
KPS 93.37 ± 5.972 
Race 
     Caucasian 
     Asian 
     South American  
     African 
     Missing 
 
73 (84.9) 
5 (5.8) 
3 (3.5) 
2 (2.3) 
3 (3.5) 
ASA 
     I 
     II 
     III 
     Missing 
 
7 (8.1) 
49 (57) 
29 (33.7) 
1 (1.2) 
Menopause  50 (58.1) 
Chronic pain >6 mos /analgesic use  25 (29.1) 
Ongoing Chronic Pain from past Sx. 15 (17.4) 
Ongoing pain problem 
     Missing 
38 (44.2) 
1 (1.2) 
Education 
     High School or Less 
     Community College  
     Bachelor’s Degree 
     Graduate Degree 
     Professional Degree 
 
13 (15.2) 
18 (20.9) 
36 (41.9) 
13 (15.2) 
6 (7) 
Living Arrangement 
     Alone 
     w/ partner 
     w/ partner, children 
     w/ children 
     w/ other 
     Missing 
 
4 (4.7) 
25 (29.1) 
46 (53.5) 
6 (7) 
4 (4.6) 
1 (1.2) 
Marital Status 
     Common Law 
     Married  
     Single 
     Separated/Divorced 
     Widowed 
 
14 (16.3) 
57 (66.3) 
4 (4.7) 
9 (10.5) 
2 (2.3) 
Have Children 71 (82.6) 
BMI: Body mass index. CCI: Charlson Comorbidity Index. KPS: Karnofsky Performance Status. ASA: American 
Society of Anesthesiologists Physical Status Classification System. Ongoing pain problem for which treatment 
has been sought.  
81 
 
Previous treatment, disease and surgical details are presented in Table 3. Most patients 
underwent a mastectomy (84.8%) and 73.3% of the sample underwent reconstruction. One 
patient had a lumpectomy on one side and a mastectomy on the other side. Duration of surgery 
ranged from 80 to 1034 mins in duration with a mean of 471.44 ± 268.71. Four patients had 
intraoperative complications. One patient experienced intraoperative premature ventricular 
contractions. One experienced venous congestion of a flap. In another patient, at the end of 
surgery flaps were found cool and a re-exploration was done. The fourth complication involved 
insufficient flow from venous anastomoses. 
The median time between the end of surgery to the post-operative follow-up was 23.79 
hours (IQR: 18.56, 41.01). Three patients underwent second surgeries before the post-operative 
follow-up was completed. Two were for hematoma evacuations and one was for failing free flaps. 
One patient experienced reduced levels of consciousness and oxygen desaturations post-
operatively which resolved with Narcan® treatment.  
Younger patients were more likely to have undergone bilateral surgery (p=.019), and 
reconstruction (p=.003) than older patients. Younger patients also had higher pain expectations 
than older patients (p=.001). Older patients were more likely to have had SLNB (p=.029). There 
were no age-related differences in KPS, CCI, other psychological (CES-D, STAI-S, STAI-T, PCS), pain 
or treatment history (pain medicine taken in past two weeks, chronic pain or analgesic use, 
previous chemotherapy or radiation, previous breast surgery, core biopsy prior to surgery), or 
surgical variables (mastectomy compared to lumpectomy, prophylactic surgery compared to 
cancer diagnosis). There was also no age difference in WHO analgesic ladder score at 24 hours.  
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Table 3. Treatment History, Disease and Surgical Details  
 Frequency (%) 
Prev. Hormonal Therapy 25 (29.1) 
Prev. Chemotherapy/Radiation 39 (45.3) 
Prev. Breast Surgery 57 (66.3) 
Pre-surgery Core biopsy  40 (46.5) 
Diagnosis 
     DCIS 
     Invasive Ductal Carcinoma 
     Invasive Lobular Carcinoma 
     Other 
     Prophylactic 
 
8 (9.3) 
30 (34.9) 
4 (4.7) 
4 (4.7) 
40 (46.5) 
Stage 
     0 
     I 
     II 
     III 
     Prophylactic 
 
9 (10.5) 
21 (24.4) 
11 (12.8) 
5 (5.8) 
40 (46.5) 
BRCA 
     1 
     2 
     Not Tested 
     Missing 
 
10 (11.6) 
7 (8.1) 
49 (57) 
4 (4.7) 
ER positive 31 (36) 
PR positive 27 (31.4) 
HER2 positive 3 (3.5) 
Procedure 
     Uni. Lumpectomy 
     Uni. Mastectomy 
     Bilat. Mastectomy 
     Mastectomy+Lumpectomy 
 
12 (14) 
34 (39.5) 
39 (45.3) 
1 (1.2) 
SLND 43 (50) 
ALND 11 (12.8) 
Reconstruction  63 (73.3) 
ER: Estrogen receptor. PR: Progesterone receptor. HER2: Her2/neu receptor. Note 40 prophylactic women and those 
diagnosed with DCIS did not have ER, PR or HER2/neu testing.   
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Baseline scores on psychological measures are presented in Table 4. 41.9% of the sample 
had scores 16 or higher on the CES-D, indicating a risk for clinical depression543. On the STAI-S, 
44.2% of patients had state anxiety classified as low (20-39)455, 45.3% had state anxiety levels 
classified as moderate (40-59)455 and 10.5% of patients had high state anxiety levels (60-80)455. 
On the STAI-T, 61.6% of patients had low anxiety (20-39)455, 30.2% had moderate anxiety (40-
59)455 and 7% had high anxiety (60-80)455.  
 
Table 4. Pre-operative Scores on Psychological Measures 
 Mean ± SD 
Average Pain Expectation 4.23 ± 1.63 
CES-D 16.11 ± 11.75 
PCS 14.51 ± 9.35 
STAI-S 41.99 ± 12.52 
STAI-T 38.09 ± 12.52 
CES-D: Centre for Epidemiologic Studies-Depression Scale. PCS: pain catastrophizing scale. STAI-S: State-trait anxiety 
scale – state subscale. STAI-T: state-trait anxiety scale-trait subscale.  
 
 
4.2 Cytokine concentrations 
There were 5 patients with IL-2 values below the curve fit, 2 cases with IL-6 values below 
the curve fit and 1 case with IL-17 values below the curve fit. Results using pairwise deletion were 
the same as with imputation therefore medians and interquartile ranges with imputed data are 
presented in Table 5. GM-CSF, IL-1b and IL-4 all had less than 30% of samples in the detection 
range so these were excluded from all subsequent analyses. Data for these cytokines are not 
presented.   
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Table 5. Pre-operative Cytokine Concentrations 
 Median Concentration (pg/ml) 
(IQR) 
IFN-g 3.248 (2.229, 5.350) 
IL-2 .123 (.057, .221) 
IL-6 .492 (.247,.818) 
IL-8 3.317 (2.115, 4.380) 
IL-10 .201 (.121, .320) 
IL-17A .516 (.318, .991) 
TGF- b 2110.847 (1399.004, 3246.473) 
TNF-a 1.353 (.933, 1.855) 
Note: IFN-g: interferon-g. IL-2: interleukin-2. IL-6: interleukin-6. IL-8: interleukin-8. IL-10: interleukin-10. IL-17A: 
interleukin-17A. TGF-b: transforming growth factor-b. TNF-a: tumour necrosis factor-a. 
 
4.3 Pain Outcomes 
Mean post-operative NRS-R was 3.07 ± 2.2 with a range of 0-8. 6 patients (7%) had severe 
resting pain (NRS-R=7-10544), 28 (32.6%) had moderate resting pain (NRS-R=4-6544), 38 (44.2%) 
had mild resting pain (NRS-R=1-3544) and 14 (16.3%) had no pain (NRS-R=0). Mean post-operative 
NRS-M was 5.4 ± 3.05 (n=83) with a range of 0-10. 34 patients (41%) had severe movement-
related pain (NRS-M=7-10), 26 (31.3%) had moderate movement-related pain (NRS-M=4-6), 15 
(18.1%) had mild movement-related pain (NRS-M=1-3) and 8 (9.6%) had no movement-related 
pain (NRS-M=0).  
The median (IQR) score on the SF-MPQ total scale was 6 (3.00, 10.63) and ranged from 
0-36. The median (IQR) scores on the SF-MPQ affective and sensory subscales were 0.5 (0, 3.00) 
and 5 (2.00, 8.25), respectively. The median (IQR) number of words chosen on the SF-MPQ total 
scale was 3.5 (2, 6); on the sensory subscale, patients chose a median of 3 words (1, 5) and on 
the affective subscale patients chose a median of 0.5 words (0, 1). The frequency that each item 
on the SF-MPQ was selected is presented in Figure 2. Words chosen by ³33% of patients have 
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been shown to be characteristic of a specific type of pain545,546. On the sensory subscale the words 
meeting the criterion of ³33% were: tender (75.6%), aching (55.1%), heavy (38.5%) and sharp 
(34.6%). On the affective subscale only tiring-exhausting (44.95%) was selected by ³33% of 
patients.  
 
Figure 2. Proportion of patients selecting each item on the SF-MPQ 
Note: Green= sensory subscale, Blue=affective subscale.  
 
The mean score on the SF-NPQ was 72.2 ± 59.9 and ranged from 0-210. The SF-NPQ can 
also be scored to distinguish between neuropathic and non-neuropathic pain. Using this 
discriminant scoring method, 22 (30.1%) patients had scores suggesting NeP and 51 (69.9%) had 
scores indicating non-neuropathic pain. Those in the probable neuropathic group were more 
likely to have had previous chemotherapy or radiation (p=.041). Patients classified as having 
probable NeP were also more likely to have had a mastectomy (p=0.013) and to have undergone 
reconstruction (p=.012). The most commonly chosen item was “increased pain due to touch” 
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with 72.6% of patients endorsing this descriptor. Numbness was chosen by 43.8% of patients and 
tingling by 19.2% (see Figure 3).  
 
Figure 3. Proportion of patients selecting each item on the SF-NPQ  
4.4 Bivariate Analysis 
There were only 11 patients (12.8%) who underwent ALND. This group of patients was 
compared to the patients who did not have ALND using independent t-tests on the four outcome 
variables and age. There were no significant differences so this variable was not considered in 
the regression models. Only 12 patients (14%) had lumpectomies however; scores on post-
operative NRS-R (p=.045), NRS-M (p=.001) and SF-NPQ (p=.027) were significantly different 
between patients who underwent mastectomy compared to lumpectomy so this variable was 
considered in the bivariate analysis. Results for the bivariate analyses with NRS-R, NRS-M, SF-
MPQ and SF-NPQ are presented in Table 6.  
Demographic factors. Younger age was associated with increased NRS-R, NRS-M and SF-
MPQ but was not associated with SF-NPQ scores.  
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Biological and health status factors. Increased IL-10 was significantly associated with 
reduced SF-NPQ scores (p=.046). Increased IL-8 was non-significantly associated with reduced 
NRS-R scores. No baseline cytokines were associated with NRS-M or SF-MPQ. BMI, CCI, KPS, and 
menopausal status were not associated with any of the outcome variables. 
Psychological factors had the greatest number of correlations meeting the criterion for 
inclusion (p=.10), with 17 out of 20 correlations reaching significance (85%). Average pain 
expectations, PCS and STAI-T were significantly positively associated with all four outcomes. STAI-
S was only associated with increased NRS-R and SF-MPQ. CES-D was also significantly associated 
with all four outcomes however, due to significant multicollinearity with STAI-T (r=.76) and STAI-
S (r=.70) it was not included as a potential predictor in the final models. Anxiety has been found 
to be a better predictor of acute post-operative pain than depression431,441. 
Surgical factors. Increased NRS-M had correlations meeting the criteria for inclusion with 
more surgical variables than the other outcomes (duration, time to follow-up, bilateral surgery, 
mastectomy, prophylactic surgery and reconstruction). SF-NPQ had the fewest significant 
correlations with surgical variables and was only associated with mastectomy (p=.002) and 
reconstruction (p=.023). Reconstruction and mastectomy were the only surgical variables 
associated with all four outcomes. Bilateral surgery, prophylactic surgery and surgical duration 
were correlated with increased NRS-R, NRS-M and SF-MPQ, however they were not significantly 
associated with SF-NPQ. Surgical duration was excluded as a potential predictor due to high 
correlation with reconstruction (r=.78). Reconstruction is more frequently reported in the 
literature on acute post-operative pain after breast cancer surgeries3,197. The number of hours 
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from the end of surgery to the follow-up was only significantly associated with increased NRS-M. 
SLNB was not associated with any of the outcome variables.  
Pain and treatment history variables demonstrated correlations meeting the criteria for 
inclusion with several pain outcomes however, there were no variables associated with all four 
outcomes. The SF-MPQ was associated with more pain and treatment history variables in 
comparison to the other pain outcomes (57%). Core biopsy prior to surgery was associated with 
reduced NRS-R, NRS-M, and SF-MPQ. Previous hormonal treatment was associated with 
increased NRS-R, NRS-M, and SF-MPQ. Previous radiation or chemotherapy was associated with 
increased NRS-R, SF-MPQ, and SF-NPQ. Previous breast surgery was associated with increased 
SF-MPQ and SF-NPQ. History of chronic pain or analgesic use greater than 6 months, having an 
ongoing pain problem and NRS-R pre-op were not associated with any of the outcomes.  
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Table 6. Bivariate Analysis with Pain Outcomes and Potential Predictor Variables 
 NRS-R (N=86) R (p) NRS-M (N=83) R (p)  Sqrt SF-MPQ (N=78) R (p) SF-NPQ R (p) (N=73) 
Demographic 
Age -.329 (.002)** -.366 (.001)*** -.235 (.038)* -.138 (.246) 
Biological and Health Status 
BMI -.017 (.880) .003 (.981) -.078 (.496) -.068 (.566) 
CCI -.060 (.582) -.079 (.477) -.054 (.640) -.089 (.455) 
KPS -.121 (.266) .007 (.952) .124 (.280) -.117 (.324) 
Menopause -1.603 (.113) -.245 (.807) -.685 (.496) .118 (.906) 
IL-2 -.178 (.103) -.006 (.956) -.077 (.504) -.077 (.519) 
IL-6 -.151 (.173) -.037 (.746) -.143 (.221) -.145 (.233) 
IL-8 -.223 (.043)* -.027 (.811) -.159 (.174) -.095 (.436) 
IL-10 -.137 (.210) .062 (.577) .018 (.873) -.238 (.044)* 
IL-17A -.098 (.374) .053 (.635) .004 (.974) .012 (.921) 
IFN-g -.054 (.623) -.023 (.841) .126 (.276) .150 (.209) 
TGF-b -.050 (.515) .039 (.726) -.051 (.659) -.033 (.779) 
TNF-a -.132 (.234) .017 (.878) .042 (.720) -.008 (.949) 
Psychological  
Avg. Expect .311 (.004)** .374 (<.001)*** .393 (<.001)*** .359 (.002)** 
CES-D .250 (.020)* .299 (.006)** .408 (<.001)*** .299 (.010)** 
PCS .330 (.002)** .253 (.021)* .329 (.003)** .283 (.015)* 
STAI-S .210 (.053) .177 (.110) .277 (.014)* .155 (.192) 
STAI-T .308 (.004)** .331 (.002)** .268 (.018)* .253 (.031)* 
Surgical 
Duration .230 (.033)* .374 (<.001)*** .201 (.077) .167 (.159) 
Time to f/up -.05 (.517) -.219 (.047)* -.037 (.749) -.011 (.928) 
SLNB -.488 (.627) -1.485 (.141) -.941 (.350) .258 (.797) 
Bilateral Sx. 3.349 (.001)*** 3.66 (<.001)*** 2.982 (.004)** 1.569 (.121) 
Mastectomy 2.038 (.045)* 3.499 (.001)*** 1.893 (.062) 3.402 (.002)** 
Prophylactic Sx. 1.917 (.059) 2.798 (.006)** 2.628 (.010)** .736 (.464) 
Reconstruction 3.286 (.001)*** 3.907 (<.001)*** 2.987 (.004)** 2.318 (.023)* 
Pain and Treatment History 
NRS-R pre-op 0.09 (.412) -.031 (.779) -.038 (.739) .121 (.308) 
Core biopsy -2.565 (.012)* -3.091 (.003)** -1.943 (.056) -.988 (.326) 
Prev Hormonal Tx 1.947 (.055) 1.784 (.078) 1.725 (.089) .510 (.611) 
Prev Rads or Chemo 1.714 (.090) 1.158 (.250) 1.755 (.083) 1.954 (.055) 
Prev. Breast Sx. 1.410 (.162) 1.543 (.127) 3.084 (.003)** 2.184 (.032)* 
Chronic pain/analg -1.273 (.206) -.515 (.608) .697 (.488) .390 (.698) 
Ongoing pain prob -.116 (.908) -1.392 (.168) .742 (.460) .093 (.926) 
Green=met criteria for inclusion in multivariate models (p<.1). *p<.05, **p£.01 ***p£.001.  
NRS-R: numeric rating scale – rest. NRS-M: numeric rating scale – movement. SF-MPQ: Short-form McGill Pain 
Questionnaire. SF-NPQ: Short-Form Neuropathic Pain Questionnaire. BMI: body mass index. CCI: Charlson 
Comorbidity Index. KPS: Karnofsky performance status. IL-2: interleukin-2, IL-6: interleukin-6. IL-8: interleukin-8. IL-
10: interleukin-10. IL-17A: interleukin-17A. IFN-g: interferon-g. TGF-b: transforming growth factor-b. TNF-a: tumour 
necrosis factor-a. Avg. Expect: average pain expectation. CES-D: center for epidemiologic studies depression scale. 
PCS: pain catastrophizing scale. STAI-S: state-trait anxiety inventory – state subscale. STAI-T: state-trait anxiety 
inventory – trait subscale. SLNB: sentinel lymph node biopsy. NRS-R pre-op: pre-operative numeric rating scale at 
rest.  
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4.5 Models 
The following variables met the criteria of p<.1 for entry into the backward regression 
models: age, baseline IL-8 and IL-10, average pain expectations, PCS, STAI-S, STAI-T, previous 
breast surgery, previous chemotherapy or radiation treatment, previous hormonal therapy, core 
biopsy prior to surgery, bilateral surgery, mastectomy, reconstruction, prophylactic surgery and 
hours to follow-up (see Table 6). Details on tests conducted to assess the assumptions of multiple 
regression for each model can be found in Appendix 3.  
NRS-R. The model for NRS-R (see Table 7) explained 29.9% of the variance in scores. This 
model included three significant variables – one demographic variable, younger age; one 
psychological variable, increased PCS; and one surgical variable, bilateral surgery. There were two 
non-significant variables that were retained in the model: increased IL-8 predicted a decrease in 
NRS-R and previous radiation or chemotherapy predicted increased NRS-R.  
NRS-M. The model for NRS-M (see Table 7) explained the greatest amount of variance, 
32.3%, and included one significant demographic variable, younger age; one significant 
psychological variable, increased STAI-T; and two significant surgical variables, bilateral surgery 
and mastectomy. No pain and treatment history variables were retained in this model.  
SF-MPQ. The model for SF-MPQ (see Table 7) explained 30.1% of the variance in the 
outcome. This model included one significant psychological variable, increased PCS; one 
significant surgical variable, bilateral surgery; one significant pain and treatment history variable, 
previous breast surgery; one non-significant demographic variable, younger age and one non-
significant biological and health status variable, decreased IL-8.  
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SF-NPQ. Of the four models developed, the model for SF-NPQ (see Table 7) explained 
the smallest amount of variance, 17.4%. Only two variables were significant, one biological and 
health status variable, reduced IL-10 and one psychological variable, increased PCS. One surgical 
variable, bilateral surgery, and one pain and treatment history variable, previous radiation or 
chemotherapy, were non-significant but retained in the model.  
Table 7. Multivariate Backwards Regression Models for Pain Outcomes 
 NRS-R (N=86) 
ba (p) 
NRS-M (N=83) 
ba (p) 
SF-MPQ (N=78) 
ba (p) 
SF-NPQ (N=73) 
ba (p) 
DEMOGRAPHIC 
AGE -.247(.013)* -.214 (.034)* -.171 (.100)  
BIOLOGICAL AND HEALTH STATUS 
IL-8 -.167 (.083)  -.163 (.112)  
IL-10    -.277 (.016)* 
PSYCHOLOGICAL 
PCS .319 (.001)***  .333 (.001)** .237 (.038)* 
STAI-T  .290 (.004)**   
SURGICAL 
BILATERAL SURGERY .290 (.004)* .243 (.022)* .280 (.008)** .201 (.076) 
MASTECTOMY  .253 (.014)*   
PAIN AND TREATMENT HISTORY 
PREV RADS OR CHEMO .154 (.107)   .189 (.095) 
PREV BREAST SURGERY   .265 (.010)**  
ADJUSTED R2 (P) .299 (<.001)*** .323 (<.001)*** .301 (<.001)*** .174 (.003)** 
*p ≤ .05, **p ≤ .01, ***p ≤ .001. a: adjusted b coefficient.  
NRS-R: numeric rating scale – rest. NRS-M: numeric rating scale – movement. SF-MPQ: Short-form McGill Pain 
Questionnaire. SF-NPQ: Short-Form Neuropathic Pain Questionnaire. IL-8: Interleukin-8. IL-10: Interleukin-10. PCS: 
pain catastrophizing scale. STAI-T: State-trait anxiety scale – trait subscale. Rads: radiation. Chemo: chemotherapy.  
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5 DISCUSSION 
As the number of patients undergoing breast surgery increases, a better understanding 
of those at risk for post-operative pain is essential. The post-operative pain experience, which 
includes both intensity and pain quality, varies widely with some patients experiencing minimal 
pain and others experiencing severe pain. The current study identified pre-operative predictors 
of pain intensity at rest, pain intensity with movement, pain qualities and neuropathic pain in the 
acute post-operative period. This is the first study, to our knowledge, that simultaneously 
identified biological, psychological, and medical correlates of multiple acute post-operative pain 
outcomes. Similarities were observed across models, however, each pain outcome also had 
unique predictors supporting the necessity of assessing multiple dimensions of the pain 
experience. Importantly, despite differences, each model included biological, psychological and 
surgical predictors. Younger age, decreased IL-10, increased pain catastrophizing, increased trait 
anxiety, bilateral surgery, mastectomy, and previous breast surgery each played a role in at least 
one of the models. Interestingly, no variable made a significant contribution to all four models.  
 
5.1 Pain Outcomes 
This study found a significant burden of acute post-operative pain despite analgesia. 
Specifically, 40% of patients experienced moderate-to-severe resting pain, and 72% had 
moderate-to-severe movement-related pain. The burden of post-operative resting pain was 
comparable to other studies of acute pain after breast cancer surgery432,436, however, the 
proportion of patients with moderate-to-severe movement-related pain was higher in this study 
compared to others436. Bruce et al. (2012) assessed patients on the 7th post-operative day and 
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asked for an average rating over the previous week which may explain the discrepancy between 
the studies. There is extensive literature examining the difference between pain reports at the 
time pain is being experienced and reports based on recall and averaging over time. Other studies 
have found recalled ratings to be inconsistent with ratings made at the time547,548. Recall and 
averaging may introduce memory, recency and primacy biases into self-report547,549,550. 
Therefore, the different assessment time frames and tasks may have contributed to the 
discrepancies in the findings of these studies.   
The most frequently selected SF-MPQ pain descriptors, tender, aching and tiring-
exhausting, were similar to the most commonly selected in other surgical populations518,519,551. A 
study on inguinal hernia repair found tender and aching were also the most commonly selected, 
however the other frequently chosen words in that study, stabbing and punishing, were selected 
by <15% of participants in the current study459. This may reflect differences in pain qualities 
across different types of surgery.  
Based on the selection of neuropathic pain qualities, which included numbness, tingling 
and pain due to touch, 30% of patients were classified as having probable neuropathic pain. A 
previous study found 10% of patients had acute neuropathic pain after mastectomy and 7% had 
neuropathic pain after breast conserving surgery552. The higher prevalence in the current study 
may be related to the measure used. In addition, the Jain et al. (2014)552 study did not specify 
whether patients had reconstruction. Despite not being retained in the final model, patients 
classified as having neuropathic pain were more likely to have had reconstruction than those not 
undergoing reconstruction. 
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In summary, measures of both pain intensity and quality indicated a high prevalence of 
acute post-operative pain despite administration of analgesics, supporting the need to better 
understand and manage pain after breast surgery. Given that acute pain is one of the most 
consistently reported predictors of chronic pain456 and that unrelieved post-operative pain 
increases the risk of various physiological and psychological adverse events4, better management 
of acute pain will not only improve the post-surgical experience but could also improve long-term 
outcomes. Understanding who is at risk for higher pain levels is essential to tailor management 
strategies and to address modifiable factors in the pre-operative period.  
 
5.2 Multidimensional Model of Pain  
Specificity theory suggested there was a one-to-one relationship between tissue damage 
and pain13. This theory has not been supported by neurobiological evidence50,553 and has largely 
been replaced by the Gate Control Theory. The Gate Control Theory explains the variable 
relationship between pain and injury by positing that nociceptive stimuli are modified in the 
spinal cord by a range of biopsychosocial factors including context, cognition, mood, genetics and 
neurochemical changes13. The interaction between the sensory-discriminative, the motivational-
affective and the cognitive-evaluative dimensions, creates the perception of pain554. These 
different dimensions may not be mediated by the same physiological substrates555 and could 
differentially contribute to different types of pain.  
The models developed in the current study supported this biopsychosocial 
conceptualization. Pain intensity at rest was predicted by younger age, bilateral surgery and 
increased pain catastrophizing. Single measurements of pain intensity have been used 
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extensively in clinical practice and provide valuable information about pain554. Most post-
operative pain research uses a unidimensional pain measurement scale as an outcome and often 
does not specify whether pain at rest or with movement is being measured516. Post-operative 
pain at rest is associated with a variety of negative outcomes including a reduced physical and 
mental quality of life in the immediate post-operative period556 highlighting the importance of 
this outcome measurement, in combination with other outcomes, in post-operative pain 
research.  
Similar to the biopsychosocial model of pain intensity at rest, movement-evoked pain 
also supported the biopsychosocial model of pain. Movement-evoked pain was predicted by 
younger age, bilateral surgery, mastectomy and greater trait anxiety. Movement-evoked pain is 
a proxy for mechanical hyperalgesia8, which is associated with central sensitization89, a key 
process in acute pain and the development of chronic post-surgical pain. Movement-evoked pain 
provides a measure of physical functioning and has been associated with delayed rehabilitation 
efforts4; therefore, the high proportion of patients experiencing severe movement-evoked pain 
warrants attention. Various studies have reported that certain pharmacological interventions are 
effective for resting pain but not movement-evoked pain4 and the small proportion of post-
operative studies assessing this outcome may contribute to the poor management of dynamic 
pain516. A recent systematic review also found acute movement-evoked pain is more frequently 
associated than resting pain with chronic post-surgical pain557. Therefore, inclusion of 
movement-evoked pain, measured separately from resting pain as a post-surgical outcome was 
essential.   
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The model developed to predict pain qualities also substantiated the biopsychosocial 
model of pain. Pain qualities were predicted by bilateral surgery, previous breast surgery and 
increased pain catastrophizing. Measures of pain quality, or how the pain feels, are also 
infrequently included in studies on acute post-operative pain in breast cancer despite being a 
principal component of the pain experience. Different pain qualities are characteristic of different 
types of pain554 and certain pain treatments are more effective for some qualities than others514. 
For instance, morphine may be more effective for relieving “throbbing”, “shooting” and “aching” 
pain qualities while gabapentin may be more effective for “tiring-exhausting” and “sickening” 
pain qualities558. Pain quality has been shown to predict the extent to which pain interferes with 
activity above the contribution of pain intensity alone520. This may impact ability to engage in 
rehabilitation efforts and return to normal activities of daily living. These differences support the 
need for post-operative care and research to consider pain qualities in addition to intensity, as 
was done in the current study.  
Finally, prediction of neuropathic pain also corroborated the multidimensional nature of 
the biopsychosocial model of pain. Neuropathic pain qualities were predicted by reduced IL-10 
and increased pain catastrophizing. Most of the post-operative literature on neuropathic pain 
has focused on chronic pain and research on acute neuropathic pain is lacking. This is the first 
study we are aware of that investigated pre-operative predictors for acute neuropathic pain 
symptoms after breast surgery. Neuropathic pain is defined as pain resulting from an injury or 
disease of the nervous system12 and has often been described as burning, tingling and numb552. 
Neuropathic pain has been shown to be more severe and distressing than nociceptive pain523 and 
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acute neuropathic pain symptoms have been reported as a risk factor for chronic pain461,559. 
Consequently, it was critical to also consider neuropathic pain in the acute post-operative period.  
Taken together, our findings support the biopsychosocial model and suggest that while 
pain intensity at rest and with movement, pain qualities and neuropathic pain symptoms are 
overlapping constructs, their distinct features may be important for both pain theory and 
management. Each model included one psychological factor, at least one biological and health 
status variable, and at least one surgical variable, although the surgical and biological and health 
status variables were not significant in all models. While the models overlapped, movement-
evoked pain, pain qualities and neuropathic pain were each predicted by unique variables, 
highlighting the need to consider multiple outcomes simultaneously to gain a complete 
understanding of the pain experience. In the next section, the contribution of each predictor is 
considered separately.  
 
5.3 Predictors of Pain Outcomes 
Demographic Correlates 
Age is a biopsychosocial phenomenon that can impact all aspects of pain444. Younger age 
has been frequently reported as a predictor for post-operative pain after breast cancer surgery 
and other surgeries3,431,434,443, however others have not found this relationship436,441,464,560. These 
discrepancies may stem from methodological differences including the assessment method used 
and consideration of confounding factors such as comorbidities and surgical and analgesic 
protocols444. In addition, the age range in different studies and degree to which the sample is 
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representative of an older population may vary444. For example, healthier older people may be 
more likely to consent to research studies444.  
In this study, younger age predicted greater resting and movement-evoked pain and 
made a non-significant contribution to predicting greater pain qualities. It was not predictive of 
neuropathic pain symptoms. Younger age likely served as a proxy for other demographic or 
psychosocial risk factors for acute pain431 and a variety of biopsychosocial as well as life-stage 
factors may have been involved444. Some have reported greater emotional distress in younger 
women prior to breast cancer surgery which could impact their post-operative pain6. In this 
study, younger patients were more likely than older patients to have had reconstruction and 
bilateral surgery which could have contributed to the increased pain in younger patients. In 
addition, younger patients expected more pain than older patients which may have exacerbated 
pain perception after surgery. A factor not measured in the current study may also underlie the 
observed relationship. This factor could be biological, for example hormone-related, 
psychological, such as the meaning attributed to the cancer, or social, for instance availability of 
social supports. The impact of variables could also change over the lifetime445 and longitudinal 
studies examining the role of various biopsychosocial factors at different life stages are needed 
to better understand the relationship between age and post-operative pain.  
Biological and Health Status Correlates  
The only baseline cytokine that was a significant predictor for any pain outcome was 
decreased IL-10, which predicted increased neuropathic pain. IL-10 is an anti-inflammatory 
cytokine that down-regulates pro-inflammatory cytokines involved in pain mechanisms126,561. A 
similar protective effect of IL-10 has been reported in chronic pain populations. In chronic pain 
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patients with a variety of conditions, plasma IL-10 was inversely correlated with pain intensity251 
and significantly lower in patients with chronic widespread pain in comparison to age and sex 
matched healthy controls150. Consistent with this, IL-10 was inversely correlated with the 
intensity of chronic neuropathic pain156. Patients with painless peripheral neuropathies also have 
higher IL-10 mRNA than patients with painful neuropathies160. Given these associations, research 
using animal models has investigated delivery of IL-10 protein, viral vectors or naked plasmid 
DNA. Delivery of IL-10 has successfully reversed neuropathic pain behaviours in animal 
models126,371,561. Therefore, the literature supports the role of IL-10 in neuropathic pain. The 
present study was the first, to our knowledge, to identify a role for pre-injury IL-10 in the 
development of acute neuropathic pain after surgery in a human model, highlighting the 
contribution of this cytokine to neuropathic pain mechanisms. The potential role of IL-10 in 
preventing neuropathic pain should be further explored.  
IL-8 was retained as a non-significant predictor in the model for resting pain and pain 
qualities. Surprisingly, increased IL-8 predicted a decrease in pain scores. IL-8 is a pro-
inflammatory cytokine involved in pain processes that is upregulated after surgery562. It has been 
shown to be increased in chronic pain populations154 and has been correlated with pain intensity 
in a variety of populations158,257. Given that most of the evidence has suggested IL-8 increases 
pain (see Table 1), reasons for the non-significant reverse relationship observed here are unclear. 
It is possible that in this model that examined baseline cytokines in combination with 
psychosocial factors to predict pain at a later time point, the role of IL-8 is less clear. However, it 
is imperative to not over-interpret this finding without replication given the lack of statistical 
significance. This needs to be further investigated prior to drawing conclusions.  
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Despite the cytokines we tested being implicated in pain mechanisms in the literature 
(see Table 1), few were retained as predictors in the four models developed. This may be due to 
the methodological approach taken in the current study. Unlike most studies that have 
considered both cytokines and pain, we measured cytokine concentrations prior to injury rather 
than examining the change in concentrations after surgery195,250,256,257,427,563–565 or once pain has 
become chronic147,148,150,153–158,162,251,561,566. It is possible that the timing of the cytokine assay in 
the trajectory of injury, recovery and chronicity is a key factor in understanding pain mechanisms. 
However, we were unable to identify any studies that have employed repeated longitudinal 
assays that consider the relationship between specific cytokines and pain. A strength of the 
current approach is in predicting risk for post-operative pain, and future studies should continue 
to explore the predictive role of baseline cytokine concentrations.    
Other biological mediators that were thought to potentially contribute to post-operative 
pain based on a literature review were not found to be significantly associated with any outcomes 
in the bivariate analysis and therefore were not considered in the multivariate models. BMI has 
been previously reported by some to be an important predictor for acute164,460 and 
chronic3,454,455,462 post-operative pain outcomes. BMI is associated with an increased 
inflammatory state567 which could contribute to baseline sensitization. While patients had a wide 
range of BMIs, it is possible that patients at the extremes were underrepresented leading to a 
lack of power to detect the impact of this factor. Patients with very low BMIs or very high BMIs 
are at increased risk for surgical complications568 and are therefore less likely to undergo surgery. 
Comorbidity score and performance status have also previously been reported to predict post-
operative pain in some studies68,197, however, no significant relationship was found in the current 
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study. Those studies used a self-report measure of comorbidities that included common 
conditions such as hypertension that are not included in the CCI. This may have contributed to 
this difference. In addition, there was a relatively small range of performance statuses in the 
present sample, again related to surgical risk criteria569, which may have contributed to the lack 
of significance of these variables. Menopause has also been associated with increased reports of 
pain in a community sample570 and changes in inflammatory cytokines after menopause571 could 
result in alterations in sensitization processes. However, similar to the current study, another 
study on breast cancer patients also found menopausal status was not an important predictor 
for post-operative pain68.  
Psychological Correlates of Acute Pain 
In line with the biopsychosocial model, psychological factors are known to be involved in 
post-operative pain441,572. Models for all pain outcomes developed in this study included one 
psychological factor as a predictor. In three of the four models, the psychological factor 
accounted for the largest amount of variance in the pain outcome emphasizing the significance 
of the psychological dimension in the pain experience.   
Pain catastrophizing, a cognitive variable that refers to the tendency to describe a painful 
experience in more exaggerated terms, to ruminate on the pain and to feel more helpless494, was 
a significant factor in the models for resting pain, pain qualities, and neuropathic pain. Pain 
catastrophizing has frequently been reported as a predictor for post-operative pain in various 
surgical populations438,441,495,496,573–575 including breast surgery434,436,573. Catastrophizing leads to 
a variety of fear responses including physiological, behavioural and cognitive responses576. The 
attentional focus on the pain stimuli and exaggerated threat value attributed to pain likely 
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contributes to pain facilitation and therefore increased pain perception494. In addition, pain 
catastrophizing leads to an aroused, negative emotional state and maladaptive pain responses, 
all of which can increase pain577. Studies have also reported that pain catastrophizing was 
associated with changes in supraspinal endogenous pain-inhibitory and facilitatory processes578. 
The diminished endogenous inhibition may have contributed to the increased post-operative 
pain seen in these patients. The role of pain catastrophizing in predicting three of the four pain 
outcomes explored in this study supports the importance of considering this variable in the pre-
operative period.  
Anxiety. Trait anxiety, a motivational-affective psychological factor that has frequently 
been reported as a correlate of post-operative pain431,441,464, predicted the greatest amount of 
variance in movement-evoked pain after surgery. Trait anxiety is characterized by a general 
tendency to perceive situations as threatening574 and is related to avoidance behavior, 
particularly with regards to anticipation of pain from certain activities576. This is consistent with 
the relationship between movement-evoked pain and trait anxiety observed in the current study. 
Individuals with high trait anxiety are generally hypersensitive to stimuli and psychologically 
more reactive441,579. The hypersensitivity to environmental threats may have contributed to the 
influence of trait anxiety on movement-related pain.  
While there is some debate as to whether pain catastrophizing and anxiety are distinct 
constructs578, they appear to be overlapping but separate components of negative affectivity. 
Anxiety relates primarily to the motivational-affective dimension of pain while pain 
catastrophizing is a component of the cognitive-evaluative dimension of pain580. A principal 
component analysis conducted by Mounce et al. (2010) found anxiety loaded on to a factor 
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designated as “general distress” while pain catastrophizing loaded on to a factor labeled 
“cognitive intrusion” supporting that these are two different constructs580. Avoidance behavior 
may have a greater impact on functional limitations while rumination and worry appear to be 
more important for resting pain states581. This may explain, in part, why in this study, anxiety was 
a predictor of movement-evoked pain while pain catastrophizing was a predictor of resting pain, 
pain qualities and neuropathic pain. 
In the current study, pain catastrophizing and trait anxiety were correlated, however, 
below the designated cut-off for multicollinearity, supporting that these are distinct aspects of 
negative affectivity. A study on breast cancer surgery found catastrophizing was associated with 
resting pain but not movement-evoked pain and the magnitude of the association between 
anxiety and movement-evoked pain was greater than that between anxiety and resting pain436. 
Catastrophizing has been found to be a mediator for anxiety in the prediction of post-operative 
pain after hysterectomy575. That study examined worst pain scores and did not specify whether 
resting pain or movement-related pain was measured, complicating comparison to the current 
study.  
The retention of a psychological factor in each model supports the Gate Control Theory, 
which proposes tissue damage stimuli are modulated by a variety of inhibitory and facilitatory 
signals in the spinal cord13. Sensory-discriminative, motivational-affective and cognitive-
evaluative dimensions are all involved in this modulation that contributes to the perception of 
pain555. The role of pain catastrophizing and anxiety in prediction of pain intensity is well-
established and this study extended the role of these variables to other pain outcomes including 
pain qualities and neuropathic pain. Additionally, and perhaps most importantly, these findings 
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suggest that psychological factors continue to play an important role in the prediction of pain 
even after controlling for surgical and biological factors.  
Surgical Correlates of Acute Pain 
Surgical variables are commonly reported as risk factors for post-operative pain. Not 
surprisingly, bilateral surgery was a predictor in three of the four models: resting pain, 
movement-evoked pain and pain qualities. An association between bilateral breast surgery and 
increased pain was also found by Schreiber et al. (2016)430. The larger surgical field may have led 
to a greater inflammatory reaction in patients undergoing bilateral than unilateral surgery which 
could have contributed to the increased pain responses in these patients. Many studies have 
excluded patients undergoing bilateral breast surgery197,435,436,461,544,573,582, however, given that 
45% of patients in this study underwent bilateral surgery, this group represents a significant 
portion of the breast surgery population. Therefore, it is essential to include these patients in 
research to enhance the external validity, representativeness and applicability of the research to 
clinical reality.  
Mastectomy, a surgical predictor in the model for movement-evoked pain, has been 
reported to be correlated with acute post-operative pain by some3,434 but not all436. Given that 
the predictive model for movement-evoked pain contained two surgical factors, surgical 
invasiveness may be particularly important for dynamic pain. More invasive surgery could elicit 
a greater inflammatory response, thereby leading to more significant sensitization and increased 
movement-evoked pain. As previously mentioned, movement-evoked pain is associated with 
mechanical hypersensitivity8 which is related to central sensitization89.  
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No surgical variable accounted for a significant portion of the variance in neuropathic 
pain, although bilateral surgery made a non-significant contribution to the model. Axillary surgery 
has been associated with acute sensory disturbances, a feature of neuropathic pain436. Some 
studies have also found ALND to contribute to the prediction of other post-operative pain 
outcomes434,435; however, Vilholm et al. (2008) did not find this583. Few women had ALND in this 
study so the predictive effect of this procedure could not be examined. Addressing the role of 
ALND in acute neuropathic pain is particularly important due to the increased risk of damage to 
the ICBN.  
Treatment and Pain History Correlates of Acute Pain  
Previous breast surgery, which predicted increased scores on the SF-MPQ, as a measure 
of pain qualities, was the only treatment and pain history variable that made a significant 
contribution to any of the models. This relationship has been previously reported in a general 
surgical population460. According to the Gate Control Theory, nociceptive inputs are modulated 
in the spinal cord by a variety of factors including past experiences555. Experience with previous 
surgery may have resulted in response shifts leading to changes in an individual’s internal 
standard of measurement or a change in values505. Previous breast surgery could also have led 
to neurobiological changes in the tissue that impacted the qualities of pain experienced after 
subsequent surgery506. Taken together, these changes may have led to facilitation in the central 
nervous system, resulting in increased pain. 
Previous radiation or chemotherapy made a non-significant contribution to predicting 
resting pain and neuropathic pain. The neurological changes resulting from radiation or 
chemotherapy, particularly taxane-based chemotherapy6,584, could have predisposed patients to 
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neuropathic pain. Since most patients receive chemotherapy or radiation therapy after surgery, 
the majority of the acute post-operative literature on breast surgery does not examine the impact 
of previous chemotherapy or radiation. One study on acute post-operative pain that did consider 
history of chemotherapy or radiation, contrary to the current study, did not find an association 
with acute post-operative pain scores3. Neither the current study nor the Fecho et al. (2009) 
study obtained information on the dosage or location of radiation, the type of chemotherapy 
received or the time-period between radiation or chemotherapy delivery and surgery. The 
reasons for the different findings in these two studies are difficult to resolve without these 
details. In addition, the lack of statistical significance observed in the current study warrants 
caution when interpreting this finding and future research should consider these details to clarify 
the role of previous radiation or chemotherapy in acute post-operative pain.  
Pre-operative pain. Contrary to some other reports440,443, pre-operative pain was not a 
predictor of post-operative pain. Many studies reporting a relationship between pre-operative 
pain and post-operative pain have been conducted in populations where pre-operative pain is 
more common, such as in joint replacement surgery437,442. In addition, studies on post-operative 
pain that have found a positive association between pre-operative pain and acute post-operative 
pain, have reported a higher incidence of pre-operative pain437,465,466,585, while studies finding no 
association have often described a population with a low burden of pre-operative pain431,432. For 
example, only 17.5% of participants in a study on breast cancer surgery had pre-operative pain 
and no association with post-operative pain was found432; however, in another study, 42% of 
patients had pre-operative pain and a significant relationship with post-operative pain was 
found436. In the current sample the burden of pre-operative pain was low with only 13 patients 
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(15.1%) reporting any pre-operative pain (NRS-R>0). The lack of association between pre-
operative and post-operative pain in the current study is consistent with other studies that had 
a small burden of pre-operative pain431,432. The small burden of pre-operative pain in the current 
study may have presented a unique opportunity to observe the impact of other factors that are 
obscured in populations with a significant burden of pain prior to surgery.  
In summary, each of the four models developed in this study included a range of 
biopsychosocial factors with similarities between the models but also differences. Younger age 
was a significant predictor for resting and movement-evoked pain intensity; IL-10 was a 
significant predictor for neuropathic pain qualities; pain catastrophizing predicted increased 
resting and movement-evoked pain intensity and neuropathic pain; trait anxiety predicted 
movement-evoked pain; bilateral surgery predicted resting and movement-evoked pain intensity 
as well as pain qualities; undergoing mastectomy instead of lumpectomy predicted increased 
movement-related pain; and previous breast surgery predicted increased pain qualities. The 
models developed supported the biopsychosocial model of pain and the necessity of considering 
factors outside of surgical procedure in understanding post-operative pain. In addition, the 
development of overlapping but unique models attested to the need to measure multiple pain 
outcomes in both post-operative research and clinical practice to improve understanding and 
management of post-operative pain.  
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5.4 Limitations 
There were several limitations of this study that need to be acknowledged. Firstly, most 
patients were Caucasian so it is unclear whether these results would apply to other ethnic groups. 
Given that this study was conducted at a single institution, findings should be confirmed in multi-
institution studies with more diverse patient populations.  
In addition, the sample size in the current study was limited, likely related to general 
challenges with research in the acute setting such as logistics before surgery, patient burden 
associated with prospective studies, or patient fatigue after surgery. Regardless, the current 
study had a sample size larger than 65% of studies cited in Table 1, supporting the acceptability. 
The number of variables included in the models was limited to ensure adequate power for the 
sample size. Furthermore, despite inclusion of a wide range of potential predictors in the 
bivariate analysis, the model predicting neuropathic pain symptoms explained a relatively small 
amount of variance, only 17.6%. Other variables not considered in this study may be related to 
neuropathic pain and this warrants further study.  
We did not correct for intra-operative or post-operative analgesia in this study. 
Standardized regimens were used at the discretion of the anesthesiologist. While patients were 
offered similar levels of “as needed” medications, challenges with both provision of analgesia by 
nursing586 and patient education on analgesia587 have been reported to contribute to poor post-
operative pain control. Other studies on acute post-operative breast pain have also not corrected 
for analgesia431,436 and this study design appropriately reflects patients’ experiences in this 
setting. However, given the potential for bias, correction for analgesic use should be considered 
in the future. 
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Finally, causation could not be definitively determined from these results, however, this 
study was prospective and longitudinal, providing support for the predictive ability of the 
considered variables.  
 
5.5 Implications and Future Directions 
Each model developed in this study contained a range of variables including demographic 
or biological, psychological and surgical variables emphasizing the biopsychosocial nature of pain 
and the importance of considering factors outside of surgical procedure in identifying patients at 
risk for severe post-operative pain. Consideration of the biopsychosocial factors identified in 
these models pre-operatively may assist with the identification of patients at high risk for post-
operative pain. Awareness of those patients at greatest risk should prompt careful monitoring in 
the post-operative period and the provision of additional resources to ensure these patients are 
adequately supported.  
In addition, this study demonstrated that while different pain outcomes are overlapping 
constructs, they have critical differences. Most studies do not measure resting pain and 
movement-evoked pain intensity separately516 and few post-operative studies assess pain 
qualities. While all four pain outcomes were significantly correlated, the identification of 
overlapping but distinct predictors for each pain outcome suggests different mechanisms may be 
involved in various components of the pain experience, consistent with the multidimensional 
model of pain555. It is essential that future post-operative pain assessment and research consider 
these different outcome measures to better understand, prevent and manage post-operative 
pain. Inclusion of only one unidimensional measure may not be adequate. In addition, whether 
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these factors also play a role in the transition to chronic post-operative pain should be 
investigated in a longitudinal study. This analysis is currently underway for the sample examined 
in the current study.  
Another important finding was the protective effect of baseline IL-10 on post-operative 
neuropathic pain. This has implications for understanding pain mechanisms and should provide 
the basis for future research investigating how this cytokine may be used as a biomarker or in 
pain prevention. As previously mentioned, there is some evidence in animal models that IL-10 
administration can prevent and reverse neuropathic pain126,371,561,588,589 and this should be 
explored. In addition, investigating the effect of local cytokine concentrations in the surgical field 
may provide more information on the autocrine and paracrine effects of inflammatory cytokines. 
Pain mechanisms involve both peripheral and central neuroplastic changes and one of the early 
steps in pain generation is the release of inflammatory cytokines from peripheral immune cells113. 
Since most cytokines operate at low concentrations, widespread concentration changes in the 
systemic circulation may be hard to identify. In addition, the site of investigation is important as 
a localized pain state may not always lead to systemic cytokine alterations428. Exploring the local 
environment could identify concentration changes at the surgical site that may not be detectable 
in the systemic circulation which could ultimately contribute to our understanding of pain 
mechanisms. The generation of IL-10 in the local tissue environment is particularly intriguing 
given that studies have shown increases in IL-10 in breast tumour tissue while systemic changes 
in IL-10 are less frequently reported590. Understanding how this local increase associated with 
breast tumour cells influences post-operative pain should be investigated, particularly 
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considering the protective effect against neuropathic pain observed in this study. This type of 
analysis could be conducted on biopsy tissue samples.  
Similarly, psychological factors have been shown to be modifiable and the inclusion of a 
psychological variable in each model has both clinical and theoretical relevance. The pre-
operative period may be a better time to address modifiable factors associated with post-
operative recovery591. Therefore, identifying patients with high levels of anxiety or pain 
catastrophizing and addressing these factors in the pre-operative period could be an effective 
way to improve post-operative pain experiences.  
A variety of psychosocial interventions have been shown to reduce anxiety, distress 
and/or pain catastrophizing and pain or physical function in various chronic pain592–596 and cancer 
populations597,598. Importantly, some of these interventions have shown sustained decreases in 
anxiety, pain catastrophizing and pain592 suggesting teaching these skills could have long-term 
positive effects for patients. Other studies have only reported changes in psychological variables 
without reporting on pain intensity599,600, however, this adds to the evidence supporting the 
modifiability of these factors.  
One challenge with this type of intervention in the pre-operative period is the extended 
duration of the therapy, with many spanning between 4-10 weeks, making use in the pre-
operative period, when the time frame between identifying a need for surgery and surgery is 
relatively short, difficult. However, some have found a single session successfully reduced pain 
catastrophizing in chronic pain patients and this reduction was maintained four weeks after the 
intervention601. They did not investigate the impact on pain however, the short duration of the 
intervention suggests this would be feasible in the pre-operative period. A review on pre-
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operative psychosocial interventions also reported the effectiveness of both pharmacological 
and non-pharmacological interventions for reducing pre-operative anxiety602.  
A variety of studies have shown a decrease in anxiety after pre-operative psychological 
or educational interventions603–605. Lin et al. (2005) also reported a simultaneous decrease in pain 
and pain interference accompanying the decrease in anxiety supporting the value of further 
investigating pre-operative interventions to address psychological risk factors prior to surgery603. 
Similar results have been reported for interventions aiming to reduce pain catastrophizing in 
surgical patients606 and chronic pain patients607.  
In terms of pharmacological interventions, Clarke et al. (2013) reported treatment with 
Gabapentin reduced both pre-operative anxiety and pain catastrophizing608. Other studies have 
also reported decreases in pre-operative anxiety using a variety of pharmacological agents602,609. 
The importance of anxiety and pain catastrophizing in predicting post-operative pain 
observed in the current study, in combination with the promising results from investigations on 
pre-operative psychosocial interventions, support the need to further explore psychosocial 
treatments to reduce pre-operative anxiety and pain catastrophizing as a preventative measure 
to reduce post-operative pain.  
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6 CONCLUSIONS 
 
In conclusion, the findings of this study strongly support the biopsychosocial model of 
pain and the need to consider biological, psychological and social factors when predicting and 
managing pain. Each pain outcome, pain intensity at rest, pain intensity with movement, pain 
qualities and neuropathic pain, was predicted by a range of biological or demographic factors, 
psychological factors and surgical factors. Critically, while the models had similarities they also 
had differences, emphasizing the importance of considering multiple pain outcomes to 
effectively prevent and treat post-operative pain. The modifiable nature of some of the variables 
in each model, in particular baseline IL-10, anxiety and pain catastrophizing, suggests these could 
represent promising targets for interventions to prevent or reduce post-operative pain after 
breast cancer surgery. The findings of this study provide a basis for future research to confirm 
the role of these risk factors and investigate interventions targeting the modifiable variables 
identified in this study.  
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APPENDICES 
 
APPENDIX A: QUESTIONNAIRES 
Short Orientation-Memory Concentration Test (SOMC) 
 
 
Time: __________                                     Patient #  __________       
                        Patient’s Initials: ___ ___ ___ 
 
Date :_____/______/_____     
              dd       mm        yy          
 
 
Short Orientation-Memory-Concentration Test (SOMC) 
 
 
Ask each question.  Score 0 for incorrect answer, and indicated score for each correct 
answer or part of answer correct.  Self-correction is allowed.  Indicate date of test at top.   
 
Question Scoring if 
correct 
 Score 
What year is it now? 4   
Answer    
What month is it now? 3   
Answer    
Repeat this address    
Address chosen (A, B, C, D)    
About what time is it now? 
(Correct if within one hour) 
3   
Answer    
Count backwards from 20 to 1 
Two points off for each error 
4 or 2   
Say the months in reverse 
order 
Two points off for each error 
4 or 2   
Repeat the address given  
Two points off for each error 
10, 8, 6,  
4, or 2 
  
 
TOTAL SCORE 
   
 
 
 
Address A                        Address B                       Address C                           Address D 
Mr. John / Brown,           Mr. Joe / Smith,                Mr. Tom / White,               Mr. Philip / Jones,  
42 / West Street,              34 / Church Road             26 / Station Road,               18 / North Way,  
Gateshead                        Banbury                            Aylesbury                           Oxford 
 
/ = marks separate items within address 
 
                                                                                                                      Researcher’s Initials: ___________ 
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Confusion Assessment Method 
 
                                                  Patient #:  _____________ 
Date: ______/______/______  Patient Initials:  ____ ____ ____ 
 dd       mm        yy             
 
Confusion Assessment Method Instrument (CAM) 
 
Acute Onset: 
 
1.  Is there evidence of an acute change in mental status from the patient’s baseline?       Yes     /     No 
 
Inattention 
  
2. A.  Did the patient have difficulty focusing attention, for example, being easily distractible, or 
having difficulty keeping track of what was being said?   (check answer below)      
 
! Not present at any time during interview. 
! Present at some time during interview, but in mild form. 
! Present at some time during interview, in marked form. 
! Uncertain. 
 
     B.    (If present or abnormal) Did this behavior fluctuate during the interview, that is, tend to come 
and go or increase and decrease in severity?    (check answer below)      
 
! Yes.  
! No. 
! Uncertain. 
! Not applicable. 
 
C. (If present or abnormal) Please describe this behavior:  
 
_______________________________________________________________________________ 
 
     _______________________________________________________________________________ 
  
 
Disorganized thinking 
 
3.   Was the patient’s thinking disorganized or incoherent, such as rambling or irrelevant 
conversation, unclear or illogical flow of ideas, or unpredictable switching from subject to subject?
 Yes     /     No 
 
Altered level of consiousness 
 
4.   Overall, how would you rate this patient’s level of consciousness? 
 
! Alert (normal). 
! Vigilent (hyperalert, overly sensitive to environmental stimuli, startled very easily). 
! Lethargic (drowsy, easily aroused). 
! Stupor (difficult to rouse). 
! Coma (unarousable). 
! Uncertain. 
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Numeric Rating Scale – Rest  
 
 
 
 
 
 
 
 
Time: __________                                                    Patient #  __________    
                         Patient’s Initials: ___ ___ ___ 
 
D te :_____/______/_____      
              dd       mm        yy          
 
 
Numeric Rating Scale – Rest  (NRS-R)  
 
 
 
 
 
 
 
 
Please circle the number below which best represents your present pain, the 
pain you are feeling right at this moment. 
 
 
 
 
0 11 2 3 4 5 6 7 8 9
Pain as bad 
as it could be0
No 
pain
 
 
 
 
 
  Researcher’s Initials: ___________ 
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Numeric Rating Scale – Movement 
 
 
 
 
 
 
 
 
 
Time: ______________                                                   Patient #  __________     
                                Patient’s Initials: ___ ___ ___ 
 
Date :_____/______/_____      
              dd       mm        yy          
 
 
Numeric Rating Scale – Movement  (NRS-M) 
 
 
Instructions: Patient is to roll from a supine to side-lying position and perform two maximal 
inspirations before rating their pain. 
 
 
 
 
 
Please circle the number below which best represents your present pain, the 
pain you are feeling right at this moment. 
 
 
 
 
0 11 2 3 4 5 6 7 8 9
Pain as bad 
as it could be0
No 
pain
 
 
 
 
 
  Researcher’s Initials: ___________ 
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Short Form McGill Pain Questionnaire 
 
 
 
Time: ______________ Patient #: ________________ 
 Patient’s Initials: _____ _____ _____ 
DATE:_____/______/_____       
              dd       mm        yy          
 
Short-Form McGill Pain Questionnaire (SF-MPQ) 
 
 
Please indicate which words best describe your pain at present.  I will read you 
each word and if the word describes your pain, I will ask you to rate the intensity 
of that characteristic as mild, moderate or severe. 
 
 NONE MILD MODERATE SEVERE 
THROBBING 0)_____ 1)____ 2)____ 3)____ 
SHOOTING 0)_____ 1)____ 2)____ 3)____ 
STABBING 0)_____ 1)____ 2)____ 3)____ 
SHARP 0)_____ 1)____ 2)____ 3)____ 
CRAMPING 0)_____ 1)____ 2)____ 3)____ 
GNAWING 0)_____ 1)____ 2)____ 3)____ 
HOT-BURNING 0)_____ 1)____ 2)____ 3)____ 
ACHING 0)_____ 1)____ 2)____ 3)____ 
HEAVY 0)_____ 1)____ 2)____ 3)____ 
TENDER 0)_____ 1)____ 2)____ 3)____ 
SPLITTING 0)_____ 1)____ 2)____ 3)____ 
TIRING-EXHAUSTING 0)_____ 1)____ 2)____ 3)____ 
SICKENING 0)_____ 1)____ 2)____ 3)____ 
FEARFUL 0)_____ 1)____ 2)____ 3)____ 
PUNISHING-CRUEL 0)_____ 1)____ 2)____ 3)____ 
 
PPI 
Please choose the word which best describes your pain at the present moment.  
0 NO PAIN  ____ 
1 MILD  ____ 
2 DISCOMFORTING ____ 
3 DISTRESSING ____ 
4 HORRIBLE  ____ 
5 EXCRUCIATING ____  
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Neuropathic Pain Questionnaire – Short Form 
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Charlson Comorbidity Index 
 
 
 
 
 
Time: __________  Patient # : _____________ 
Date: ___ / ___ / _____  Patient  Initials:  _____ _____ _____ 
           dd     mm    yyyy 
Charlson Comorbidity Index (CCI) 
(Charlson et al., 1987) 
  
 
Patient Age: ______________ years 
 
Does the Patient Have: (check appropriate response) 
 
AIDS?     __ YES      __ NO 
 
Cerebrovascular Disease?  __ YES  __ NO 
 
Chronic Pulmonary Disease?  __ YES  __ NO 
 
Congestive Heart Failure?  __ YES  __ NO 
 
Connective Tissue Disease?  __ YES  __ NO 
 
Dementia?     __ YES  __ NO 
 
Hemiplegia?    __ YES  __ NO 
 
Leukemia?    __ YES   __ NO 
 
Malignant Lymphoma ?  __ YES  __ NO 
 
Myocardial Infarction?  __ YES  __ NO 
 
Peripheral Vascular Disease?  __ YES  __ NO 
 
Ulcer Disease?   __ YES  __ NO 
 
 
Select the appropriate column for each condition; give only 1 answer per row 
 
Diabetes Mellitus __ NONE __ Without __ With End Organ 
                     End Organ        Damage 
          Damage 
 
Liver Disease  __ NONE __ MILD __ MODERATE __ SEVERE 
 
Renal Disease  __ NONE __ MILD __ MODERATE   __ SEVERE 
 
Malignant Solid __ NONE __ MILD __ MODERATE __ SEVERE 
Tumour 
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Karnofsky Performance Index 
 
 
 
 
Time: ______________  Patient # : _____________ 
Date: ___ / ___ / _____  Patient  Initials:  _____ _____ _____ 
           dd     mm    yyyy  
 
 
Karnofsky Performance Index (KPI) 
 
 
 
100 Normal, no complaints, no evidence of disease 
 
 90 Able to carry on normal activity, minor signs or symptoms of disease 
 
80 Normal activity with effort, some signs or symptoms of disease 
 
70 Cares for self.  Unable to carry on normal activity or to do active work 
 
60 Requires occasional assistance, but is able to care for most of his needs 
 
50 Requires considerable assistance and frequent medical care 
 
40 Disables, requires special care and assistance  
 
30 Severely disabled, hospitalization is indicated although death is not imminent 
 
20 Hospitalization is necessary, very sick, active supportive treatment necessary 
 
10 Moribund, fatal processes progressing rapidly 
 
0 Dead 
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Centre for Epidemiologic Studies – Depression Scale 
 
ID: _____                      Pain after breast cancer treatment  
Date: __/__/__    
 
 
Page 1 of 2 
Version 1 
December 1, 2013   
 
CES-D 
 
Below is a list of the ways you might have felt or behaved. Please tell me how 
often you have felt this way during the past week. 
 
  Rarely or none of the time (less than 1 day) 
  Some or a little of the time (1-2 days) 
  Occasionally or a moderate amount of the time (3-4 days) 
  Most or all of the time (5-7 days) 
 
During the Past Week          Rarely   A little   Moderate    Most 
 
1. I was bothered by things that usually 
don’t bother me…………………………….  
 
2. I did not feel like eating; my appetite 
was poor……………………………………. 
 
3. I felt that I could not shake off the blues 
Even with help from my family or friends…. 
 
     4.  I felt that I was just as good as other people... 
 
     5.  I had trouble keeping my mind on what I  
          was doing…………………………………... 
 
     6.  I felt depressed……………………………… 
 
     7.  I felt that everything I did was an effort……. 
 
     8.  I felt hopeful about the future………………. 
 
     9.  I thought my life had been a failure………… 
 
    10. I felt fearful…………………………………. 
 
    11. My sleep was restless………………………. 
 
    12. I was happy…………………………………. 
0 1      2  3 
0 1      2  3 
0 1      2  3 
0 1      2  3 
0 1      2  3 
0 1      2  3 
0 1      2  3 
0 1      2  3 
0 1      2  3 
0 1      2  3 
0 1      2  3 
0 1      2  3 
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Pain Catastrophizing Scale 
 
   
Time: ______________   Patient # : _____________ 
Date: ___ / ___ / _____  Patient  Initials:  _____ _____ _____ 
           dd     mm    yyyy  
  
  
 
 
Pain Catastrophizing Scale (PCS) 
 
Everyone experiences painful situations at some point in their lives.  
Such experiences may include headaches, tooth pain, joint or muscle 
pain.  People are often exposed to situations that may cause pain such as 
illness, injury, dental procedures or surgery. 
 
We are interested in the types of thoughts and feelings that you have 
when you are in pain.  Listed below are thirteen statements describing 
different thoughts and feelings that may be associated with pain.  Using 
the following scale, please indicate the degree to which you have these 
thoughts and feelings when you are experiencing pain.   
 
 
0 
 
1 
 
2 
 
3 
 
4 
 
Not at all 
 
To a slight 
degree 
 
To a 
moderate 
degree 
 
 
To a great 
degree 
 
All the time 
 
 
When I am in pain… 
 
1. I worry all the time about whether 
the pain will end. 
 
1 2 3 4 5
2. I feel I can’t go on. 
 
1 2 3 4 5
3. It’s terrible and I think it’s never 
going to get any better. 
1 2 3 4 5
4. It’s awful and I feel that it 
overwhelms me.  
 
1 2 3 4 5
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State-Trait Anxiety Inventory – State subscale 
 
 
 
 
 
Time: ___________  Patient #:_______________                                     
Patient’s Initials: ____ ____ ____  
Date: ____________ 
             dd/mm/yy 
 
State-Trait Anxiety Inventory (STAI-S) 
 
DIRECTIONS: A number of statements which people have used to describe themselves are 
given below. Read each statement and then blacken the appropriate circle to the right of the 
statement to indicate how you feel right now, that is, at this moment. There are no right or wrong 
answers. Do not spend too much time on any one statement but give the answers which seem to 
describe your present feelings best. 
no
t a
t a
ll
so
m
ew
ha
t
mo
de
ra
te
ly 
so
ve
ry
 m
uc
h s
o
 
1. I feel calm .. .....................................................................................................  
2. I feel secure ......................................................................................................  
3. I am tense ........................................................................................................  
4. I am regretful....................................................................................................  
5. I feel at ease ....................................................................................................  
6. I feel upset .......................................................................................................  
7. I am presently worrying over possible misfortunes ........................................  
8. I feel rested ......................................................................................................  
9. I feel anxious ...................................................................................................  
10. I feel comfortable ..........................................................................................  
11. I feel self-confident .......................................................................................  
12. I feel nervous ................................................................................................  
13. I am jittery .....................................................................................................  
14. I feel “high strung” ........................................................................................  
15. I am relaxed ...................................................................................................  
16. I feel content .................................................................................................  
17. I am worried ..................................................................................................  
18. I feel over-excited and “rattled” ....................................................................  
19. I feel joyful ....................................................................................................  
20. I feel pleasant .................................................................................................  
  Researcher’s Initials: _____ 
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State-Trait Anxiety Inventory – Trait subscale 
Mastectomy Study  Patient Initials:  ______  _____  _____ 
Date:  _______________________   Time: __________________ Patient ID:  ______________ 
STAI - T 
 
Instructions: Read each statement and then select the appropriate response to indicate how you 
generally feel.  Do not spend too much time on any one statement, but give the answer which 
seems to describe your present feelings best. 
      
 Not At All A Little Somewhat Very Much So 
 
 
1.  I feel calm  
 
    
2.  I feel secure  
 
    
3.  I feel tense  
 
    
4. I feel strained  
 
    
5. I feel at ease  
 
    
6. I feel upset  
 
    
7. I am presently worrying  
over possible misfortunes  
 
    
8. I feel satisfied  
 
    
9. I feel frightened  
 
    
10. I feel uncomfortable  
 
    
11. I feel self confident       
12. I feel nervous     
13. I feel jittery  
 
    
14. I feel indecisive  
 
    
15. I am relaxed  
 
    
16. I feel content 
 
    
17. I am worried  
 
    
18. I feel confused 
 
    
19. I feel steady  
 
    
20. I feel pleasant  
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APPENDIX B: DATA COLLECTION TIMELINE  
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APPENDIX C: MODEL ASSUMPTION TESTING 
NRS-R  
The Durbin-Watson statistic for the NRS-R model was 1.836. The average variance inflation factor 
(VIF) value, a measure of multicollinearity, was 1.057, indicating no multicollinearity. Outliers 
were assessed using standardized residuals. 7.2% of standardized residuals were above 2 and the 
largest standardized residual had an absolute value of 2.14 suggesting no outliers. The 
standardized residuals were normal based on a histogram and z-values of skewness and kurtosis. 
All Cook’s distance values were below 1 and the highest value was 0.085. All leverage values were 
below the proposed cut-off suggesting no cases exerted undue influence on the model.  
 
NRS-M 
The Durbin-Watson statistic for this model was 1.657. The average VIF value was 1.1535. All 
standardized residuals were below the cut-off of 3.3. The model for movement-evoked pain had 
one individual with a standardized residual of 3.177. All leverage values were below the 
designated cut-off and all Cook’s distances were below the threshold of 1. In addition, the 
standardized residuals were normal according to a histogram and z-scores of skewness and 
kurtosis. There were only two cases with standardized residuals greater than 2, so a total of 2.4% 
of cases were above 2.  
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SF-MPQ 
The Durbin-Watson statistic for the model predicting SF-MPQ scores was 1.535. The average VIF 
value was 1.067. VIF values met the designated criteria to prevent multicollinearity. Standardized 
residuals were normal and all were below 3. The largest was 2.79. The largest Cook’s distance 
was 0.154 and all leverage points were below the designated cut-off.  
 
SF-NPQ 
The Durbin-Watson statistic was 1.545. The average VIF value in the final model was 1.02, 
indicating no multicollinearity issues. Standardized residuals were normally distributed based on 
a histogram and z-scores of skewness and kurtosis. The highest standardized residual was 2.16. 
The highest Cook’s distance was 0.11 and all leverage values were below the designated cut-off.  
 
 
 
 
